{"366958222c78b36dc18e8dcce27de2b1575bd9b3": [["AbstractThe laboratory response to the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic may be termed heroic.", [["acute respiratory syndrome coronavirus", "DISEASE", 54, 92], ["SARS-CoV-2", "ORGANISM", 96, 106], ["severe acute respiratory syndrome coronavirus", "SPECIES", 47, 92], ["SARS-CoV-2", "SPECIES", 96, 106], ["the current severe acute respiratory syndrome coronavirus", "PROBLEM", 35, 92], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["pandemic", "PROBLEM", 108, 116], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["respiratory syndrome", "OBSERVATION", 60, 80], ["heroic", "OBSERVATION", 131, 137]]], ["From the identification of the novel coronavirus to implementation of routine laboratory testing around the world to the development of potential vaccines, laboratories have played a critical role in the efforts to curtail this pandemic.", [["coronavirus", "ORGANISM", 37, 48], ["routine laboratory testing", "TEST", 70, 96], ["potential vaccines", "TREATMENT", 136, 154]]], ["In this brief report, we review our own effort at a mid-sized, rural, academic medical center to implement a molecular test for the virus; and, we share insights and lessons learned from that process which might be helpful in similar situations in the future.AbstractAs news began to disseminate from Wuhan, China toward the end of 2019 and in early 2020 of a novel coronavirus and its rapid spread throughout that country, we began to think about the potential implications if the virus were to come to the United States.", [["coronavirus", "DISEASE", 366, 377], ["coronavirus", "ORGANISM", 366, 377], ["a molecular test", "TEST", 107, 123], ["the virus", "PROBLEM", 128, 137], ["a novel coronavirus", "PROBLEM", 358, 377], ["the virus", "PROBLEM", 478, 487]]], ["From a laboratory perspective, we had three major initial concerns regarding clinical molecular testing for SARS-CoV-2: i) which test and which instrument would be ideal, ii) the availability of reagents and other supplies to perform the testing and uncertainty about the number of samples which we might receive, and iii) the laboratory workflow with respect to safety.AbstractOver the next few weeks, it became clear that the spread of the novel coronavirus, now known as SARS-CoV-2, would impact more countries than just China, and on March 11 th , 2020 the World Health Organization (WHO) declared SARS-CoV-2 a pandemic.", [["SARS", "DISEASE", 108, 112], ["coronavirus", "DISEASE", 448, 459], ["SARS", "DISEASE", 474, 478], ["coronavirus", "ORGANISM", 448, 459], ["SARS-CoV-2", "ORGANISM", 474, 484], ["SARS-CoV", "SPECIES", 474, 482], ["SARS-CoV", "SPECIES", 602, 610], ["clinical molecular testing", "TEST", 77, 103], ["SARS", "PROBLEM", 108, 112], ["the testing", "TEST", 234, 245], ["the novel coronavirus", "PROBLEM", 438, 459]]], ["An alarm was triggered for us when an initial attempt by the CDC to provide testing materials to state laboratories resulted in withdrawal of test kits due to contamination issues of reagents for one target region (N3) which was later removed, with resultant delays in developing early national testing capabilities.", [["testing materials", "TEST", 76, 93], ["test kits", "TEST", 142, 151], ["contamination issues", "PROBLEM", 159, 179], ["reagents", "TREATMENT", 183, 191], ["resultant delays", "PROBLEM", 249, 265]]], ["And a clock began ticking with respect to our own laboratory's response to an evolving national crisis.AbstractAs we explored the possibilities of developing testing in-house, we were immediately met by the peremptory challenge that the Centers for Disease Control (CDC) and the State Health Laboratory Network would perform all initial testing.", [["an evolving national crisis", "PROBLEM", 75, 102], ["all initial testing", "TEST", 325, 344], ["crisis", "OBSERVATION", 96, 102]]], ["While the CDC has significant expertise in dealing with such crises, a limiting factor that is often overlooked and became evident in the SARS-CoV-2 pandemic, is that State Public Health Laboratories are under-resourced to function in this expected role.", [["SARS-CoV-2 pandemic", "DISEASE", 138, 157], ["SARS-CoV-2", "ORGANISM", 138, 148], ["such crises", "PROBLEM", 56, 67], ["the SARS", "PROBLEM", 134, 142], ["significant", "OBSERVATION_MODIFIER", 18, 29]]], ["In addition, the hurdles to developing and/or validating a laboratory developed test (LDT) for SARS-CoV2 became much greater when a Public Health Emergency was declared by the secretary of Health and Human Services on January 31 st 2020 (pursuant to Section 564(b)(1)(C) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \u00a7360bbb-3)) and the CDC assay was subsequently granted emergency use authorization on February 4th by the FDA.", [["SARS", "DISEASE", 95, 99], ["Human", "ORGANISM", 200, 205], ["Human", "SPECIES", 200, 205], ["LDT", "TEST", 86, 89], ["SARS", "PROBLEM", 95, 99], ["the CDC assay", "TEST", 342, 355]]], ["This declaration, while fast-tracking approval of a first diagnostic test for an emerging public health threat concurrently raises the bar and regulatory hurdles for developing and/or validating laboratory-developed tests.AbstractConcerned that the efforts of state laboratories would be further impacted by lack of resources, we began to identify sources -including the WHO, the CDC, and commercial vendors -of the required primers and probes for the reverse transcriptase polymerase chain reaction (RT-PCR) detection of the virus and placed orders for test reagents from potential suppliers.", [["reverse transcriptase", "PROTEIN", 452, 473], ["a first diagnostic test", "TEST", 50, 73], ["tests", "TEST", 216, 221], ["the reverse transcriptase polymerase chain reaction", "TREATMENT", 448, 499], ["RT-PCR", "TEST", 501, 507], ["the virus", "PROBLEM", 522, 531], ["test reagents", "TEST", 554, 567]]], ["The requested reagents included those needed for both manual and automated extraction of RNA from respiratory specimens.AbstractConcerned that reagents might prove scarce, our plan was to evaluate and validate several extraction methods and RT-PCR assays simultaneously, with the hope that we would obtain a sufficient quantity of reagents to successfully initiate and maintain testing with one or more methods.AbstractOn February 29, 2020, the FDA issued the following directive: \"Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing Under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency\".", [["respiratory specimens", "ANATOMY", 98, 119], ["Coronavirus Disease", "DISEASE", 626, 645], ["both manual and automated extraction of RNA", "TREATMENT", 49, 92], ["respiratory specimens", "TEST", 98, 119], ["several extraction methods", "TEST", 210, 236], ["RT-PCR assays", "TEST", 241, 254], ["testing", "TEST", 378, 385], ["Diagnostics Testing", "TEST", 493, 512], ["Coronavirus Disease", "PROBLEM", 626, 645]]], ["The document provided guidance for high complexity testing laboratories developing SARS-CoV-2 tests for submission for Emergency Use Authorization (EUA) status with respect to required validation experiments and reporting to the FDA.", [["SARS", "DISEASE", 83, 87], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["validation experiments", "TREATMENT", 185, 207]]], ["The policy stipulated that the required experimental data would include analytical sensitivity/limit of detection (LOD), clinical evaluation (accuracy), inclusivity, and cross reactivity testing.AbstractThe latter two criteria could be determined in silico but LOD and clinical evaluation would need to be determined with positive samples.", [["samples", "ANATOMY", 331, 338], ["analytical sensitivity", "TEST", 72, 94], ["clinical evaluation", "TEST", 121, 140], ["accuracy", "TEST", 142, 150], ["cross reactivity testing", "TEST", 170, 194], ["clinical evaluation", "TEST", 269, 288]]], ["Importantly, once internally validated, clinical testing by high-complexity laboratories could begin immediately with a 15-day grace period before submission of the validation study to the FDA.AbstractGiven a lack of positive samples, the FDA allowed for the use of \"contrived samples\" that is, specimens in which known positive amounts of virus or viral RNA had been \"spiked\" into the samples.AbstractWhile well-meaning, the guidelines proved problematic since our laboratory lacked the control RNA to perform these experiments and dealing with live virus required a Biosafety Level 3 (BSL3) facility, which, like most teaching hospitals, we lack.", [["samples", "ANATOMY", 226, 233], ["samples", "ANATOMY", 277, 284], ["specimens", "ANATOMY", 295, 304], ["samples", "ANATOMY", 386, 393], ["viral RNA", "RNA", 349, 358], ["clinical testing", "TEST", 40, 56], ["the validation study", "TEST", 161, 181], ["specimens", "TEST", 295, 304], ["positive amounts of virus", "PROBLEM", 320, 345], ["viral RNA", "PROBLEM", 349, 358], ["our laboratory", "TEST", 462, 476], ["these experiments", "TREATMENT", 511, 528], ["live virus", "PROBLEM", 546, 556]]], ["While other control material such as synthetic controls and plasmids became available, the FDA maintained the need to use purified viral RNA and identified a vendor which could supply it.", [["plasmids", "DNA", 60, 68], ["viral RNA", "RNA", 131, 140], ["synthetic controls and plasmids", "TREATMENT", 37, 68], ["purified viral RNA", "PROBLEM", 122, 140]]], ["Initially laboratories were required to spike RNA transcripts into previously extracted nucleic acid from negative samples for the CDC assay to determine the limit of detection but this had its own challenges of not representing extraction of true clinical samples and issues with degradation were identified.", [["samples", "ANATOMY", 115, 122], ["samples", "ANATOMY", 257, 264], ["nucleic acid", "CHEMICAL", 88, 100], ["spike RNA transcripts", "RNA", 40, 61], ["nucleic acid", "TEST", 88, 100], ["the CDC assay", "TEST", 127, 140], ["true clinical samples", "PROBLEM", 243, 264]]], ["We were then able, according to the FDA, spike purified viral RNA into crude patient specimens before performing the RNA extraction and RT-PCR portions of the procedure.AbstractWhile this represented a positive clinical sample to the best of the laboratory's ability, it still did not fully account for the extraction efficiency from viral particles in a clinical specimen and naked RNA spiked into transport media or negative clinical specimens tended to degrade more rapidly.AbstractDuring an informational conference call hosted by the FDA, laboratories requested to be able to use synthetic control materials, but the agency remained steadfast in its decision.", [["specimens", "ANATOMY", 85, 94], ["specimen", "ANATOMY", 364, 372], ["specimens", "ANATOMY", 436, 445], ["patient", "ORGANISM", 77, 84], ["viral RNA", "RNA", 56, 65], ["patient", "SPECIES", 77, 84], ["the RNA extraction", "TREATMENT", 113, 131], ["RT-PCR portions", "TREATMENT", 136, 151], ["the procedure", "TREATMENT", 155, 168], ["the extraction efficiency", "PROBLEM", 303, 328], ["viral particles", "PROBLEM", 334, 349], ["a clinical specimen", "TEST", 353, 372], ["synthetic control materials", "TREATMENT", 585, 612], ["viral particles", "OBSERVATION", 334, 349]]], ["As laboratories began to place orders for the RNA control, another bottleneck in the development and validation of laboratory testing became evident, as the supplier could not distribute this required material at a sufficient pace.", [["the RNA control", "TREATMENT", 42, 57], ["laboratory testing", "TEST", 115, 133]]], ["Although we had several synthetic and plasmid controls sitting in our freezer, we were not allowed to use them for the \"spike-in\" experiments.", [["several synthetic and plasmid controls sitting", "TREATMENT", 16, 62], ["the \"spike", "PROBLEM", 115, 125]]], ["Moreover, during multiple attempts to order the FDA-mandated RNA control, we were asked to complete numerous forms and applications that required signatures from institutional administrators who were already in the midst of dealing with the broader, evolving hospital virus crisis, creating an additional stress point.", [["the FDA-mandated RNA control", "TREATMENT", 44, 72], ["evolving hospital virus crisis", "PROBLEM", 250, 280], ["hospital virus crisis", "OBSERVATION", 259, 280]]], ["After significant feedback from clinical laboratories, the FDA indicated that the use of some synthetic control materials (in vitro RNA transcripts) could be used for the \"spike-in\" experiments one week after we had finally obtained the recommended RNA material.", [["in vitro RNA transcripts", "RNA", 123, 147], ["clinical laboratories", "TEST", 32, 53], ["some synthetic control materials", "TREATMENT", 89, 121], ["vitro RNA transcripts", "TREATMENT", 126, 147], ["the \"spike", "PROBLEM", 167, 177]]], ["We chose to implement a verification strategy that would align with both emerging EUA guidance from the FDA and our standard requirements as a clinical molecular diagnostic laboratory operating under our usual regulatory framework of Clinical Laboratory Improvement Amendments (CLIA) certification and accreditation through the College of American Pathologists (CAP).", [["a verification strategy", "TREATMENT", 22, 45]]], ["Our plan included the production of enough contrived clinical specimens and control material to proceed with validation or verification of the multiple (laboratory-developed and CDC EUA) tests that we were evaluating.AbstractIn an attempt to match approved RNA extraction methods with RT-PCR assays, we were able to extract enough nucleic acid samples to evaluate and/or validate multiple RT-PCR assays without the need for further extractions.", [["specimens", "ANATOMY", 62, 71], ["RNA extraction methods", "TREATMENT", 257, 279], ["RT-PCR assays", "TEST", 285, 298], ["nucleic acid samples", "TEST", 331, 351], ["multiple RT-PCR assays", "TEST", 380, 402], ["further extractions", "TREATMENT", 424, 443]]], ["In essence we created a \"validation set\" of extracted samples.", [["samples", "ANATOMY", 54, 61], ["extracted samples", "PROBLEM", 44, 61]]], ["The set included four known positive and four known negative patient samples that we obtained from the New Hampshire Public Health Laboratory (the authors gratefully acknowledge the support of Drs. Christine Bean and Fengxiang Gao), several presumed negative samples that had previously been tested for other bacterial/viral infections, and several positive contrived specimens (spiked with viral RNA or known positive patient specimens).", [["samples", "ANATOMY", 259, 266], ["specimens", "ANATOMY", 368, 377], ["specimens", "ANATOMY", 427, 436], ["viral infections", "DISEASE", 319, 335], ["patient", "ORGANISM", 61, 68], ["specimens", "CANCER", 368, 377], ["patient", "ORGANISM", 419, 426], ["specimens", "CANCER", 427, 436], ["viral RNA", "RNA", 391, 400], ["patient", "SPECIES", 61, 68], ["patient", "SPECIES", 419, 426], ["other bacterial/viral infections", "PROBLEM", 303, 335], ["several positive contrived specimens", "PROBLEM", 341, 377], ["viral RNA", "PROBLEM", 391, 400], ["known positive patient specimens", "PROBLEM", 404, 436], ["positive", "OBSERVATION_MODIFIER", 28, 36], ["viral infections", "OBSERVATION", 319, 335]]], ["In addition, we prepared standard operating procedures for the different extraction methods and RT-PCR assays as well as training documentation and worksheets.", [["the different extraction methods", "TREATMENT", 59, 91], ["RT-PCR assays", "TEST", 96, 109], ["training documentation", "TEST", 121, 143]]], ["These \"verification\" studies, while addressing typical performance characterisitcs of a test, were minimal compared to what a validation study would entail for a qualitative molecular test in our laboratory.AbstractSafety risk assessments were performed for working areas of the laboratory and for specimen receiving/transport.", [["specimen", "ANATOMY", 298, 306], ["These \"verification\" studies", "TEST", 0, 28], ["a test", "TEST", 86, 92], ["a validation study", "TEST", 124, 142], ["a qualitative molecular test", "TEST", 160, 188], ["AbstractSafety risk assessments", "TEST", 207, 238]]], ["As a result, we modified our normal personal protective equipment (PPE) requirements (eye protection, disposable gloves and an impervious lab coat) to also include the use of face shields and masks while processing raw samples in a biosafety cabinet.", [["eye", "ANATOMY", 86, 89], ["eye", "ORGANISM_SUBDIVISION", 86, 89], ["eye protection", "TREATMENT", 86, 100], ["disposable gloves", "TREATMENT", 102, 119], ["face shields", "TREATMENT", 175, 187], ["masks", "TREATMENT", 192, 197]]], ["We also implemented additional precautions for waste disposal (use of a double bagging technique and trash removal by molecular staff to minimize foot traffic in the laboratory) and modifications to hand washing and hand sanitizing practices (required hand washing between glove changes and increased frequency of glove changes).", [["hand", "ANATOMY", 199, 203], ["hand", "ANATOMY", 216, 220], ["hand", "ANATOMY", 252, 256], ["foot", "ORGANISM_SUBDIVISION", 146, 150], ["hand", "ORGANISM_SUBDIVISION", 199, 203], ["hand", "ORGANISM_SUBDIVISION", 216, 220], ["hand", "ORGANISM_SUBDIVISION", 252, 256], ["additional precautions", "TREATMENT", 20, 42], ["waste disposal", "TREATMENT", 47, 61], ["a double bagging technique", "TREATMENT", 70, 96], ["trash removal", "TREATMENT", 101, 114], ["hand washing", "TREATMENT", 199, 211], ["hand sanitizing practices", "TREATMENT", 216, 241], ["hand washing", "TREATMENT", 252, 264], ["glove changes", "TREATMENT", 273, 286], ["glove changes", "TREATMENT", 314, 327], ["foot", "ANATOMY", 146, 150]]], ["Remarkably, we began to perform patient testing less than one week after obtaining the materials to perform these validation steps.AbstractAs much as biomedical laboratories practice preparedness for situations such as this pandemic, there inevitably are unknown variables.", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["patient testing", "TEST", 32, 47], ["this pandemic", "PROBLEM", 219, 232]]], ["One \"unknown\" -that we now know only too well and that is thwarting larger scale implementation of testing at our medical center -is the nation-wide shortage of collection swabs and transport media.", [["collection swabs", "TEST", 161, 177], ["transport media", "TREATMENT", 182, 197]]], ["While laboratories have the ability to use alternative transport media including saline, there is little we can do without collection devices.", [["saline", "SIMPLE_CHEMICAL", 81, 87], ["alternative transport media", "TREATMENT", 43, 70], ["saline", "TREATMENT", 81, 87], ["collection devices", "TREATMENT", 123, 141]]], ["As each swab type used in clinical laboratory testing was eventually approved for use in assays, national supplies became exhausted.", [["clinical laboratory testing", "TEST", 26, 53], ["exhausted", "PROBLEM", 122, 131]]], ["Viral transport media, historically a transport media used for molecular detection of viruses, was also becoming depleted across the country.", [["Viral transport media", "TREATMENT", 0, 21], ["a transport media", "TREATMENT", 36, 53], ["viruses", "PROBLEM", 86, 93], ["viruses", "OBSERVATION", 86, 93], ["depleted", "OBSERVATION", 113, 121]]], ["Fear and chaos resulted from not knowing all the clinical challenges this virus would present, how many people would be infected and become symptomatic, the degree of severity of those symptoms and how many people could potentially die.", [["people", "ORGANISM", 104, 110], ["people", "ORGANISM", 207, 213], ["people", "SPECIES", 104, 110], ["people", "SPECIES", 207, 213], ["symptomatic", "PROBLEM", 140, 151], ["those symptoms", "PROBLEM", 179, 193], ["symptomatic", "OBSERVATION_MODIFIER", 140, 151]]], ["As outlined above, we and other laboratory scientists quickly marshalled teams to develop and implement tests for the virus that hopefully will help shed light on these questions and prevent wide-scale panic and deaths.AbstractWe certainly hope that we do not see another pandemic such as SARS-CoV-2, but it is na\u00efve to think another one will never occur.", [["panic", "DISEASE", 202, 207], ["deaths", "DISEASE", 212, 218], ["SARS", "DISEASE", 289, 293], ["SARS-CoV-2", "ORGANISM", 289, 299], ["SARS-CoV", "SPECIES", 289, 297], ["the virus", "PROBLEM", 114, 123], ["wide-scale panic and deaths", "PROBLEM", 191, 218]]], ["To plan for potential future outbreaks, laboratories should be prepared and equipped to rapidly identify the pathogen; the evolution of third and fourth generations of massively parallel sequencing technologies should make this possible.", [["the pathogen", "PROBLEM", 105, 117], ["massively parallel sequencing technologies", "TREATMENT", 168, 210], ["pathogen", "OBSERVATION", 109, 117]]], ["Molecular-based testing with a variety of real time PCR platforms should be granted rapid EUA status for use of standardized primer/probe sequences in conjunction with multiple specimen types and extraction methods.", [["specimen", "ANATOMY", 177, 185], ["primer/probe sequences", "DNA", 125, 147], ["Molecular-based testing", "TEST", 0, 23], ["real time PCR platforms", "TEST", 42, 65], ["standardized primer/probe sequences", "TREATMENT", 112, 147], ["multiple specimen types", "TREATMENT", 168, 191], ["extraction methods", "TREATMENT", 196, 214]]], ["Federal agencies should be better prepared to distribute control materials as well as test reagents to laboratories operating outside of the State Health Laboratory network.", [["test reagents", "TEST", 86, 99]]], ["While high complexity molecular testing should be restricted to those laboratories accredited to do such work, more flexibility to develop tests needed to curtail a pandemic should be granted to these laboratories under an EUA.AbstractFinally, a global crisis is not the appropriate time for finger pointing among countries, agencies, vendors, laboratories, healthcare workers, and population sectors.", [["finger", "ANATOMY", 292, 298], ["finger", "ORGANISM_SUBDIVISION", 292, 298], ["tests", "TEST", 139, 144], ["a pandemic", "PROBLEM", 163, 173], ["a global crisis", "PROBLEM", 244, 259], ["global", "OBSERVATION_MODIFIER", 246, 252], ["crisis", "OBSERVATION", 253, 259]]]], "71c8a1e18ce8e334828e23a9a4556ffa0ae29fb5": [["INTRODUCTIONThe novel coronavirus outbreak, which began as an epidemic in Wuhan, China, in December 2019 has been confirmed to In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic.", [["coronavirus outbreak", "DISEASE", 22, 42], ["SARS", "DISEASE", 195, 199], ["coronavirus", "ORGANISM", 22, 33], ["SARS-CoV-2", "ORGANISM", 195, 205], ["coronavirus", "SPECIES", 22, 33], ["SARS-CoV", "SPECIES", 195, 203], ["The novel coronavirus outbreak", "PROBLEM", 12, 42], ["SARS", "PROBLEM", 195, 199], ["CoV", "TEST", 200, 203], ["a global pandemic", "PROBLEM", 206, 223], ["coronavirus outbreak", "OBSERVATION", 22, 42]]], ["To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths.", [["coronavirus disease", "DISEASE", 9, 28], ["COVID-19", "CHEMICAL", 35, 43], ["deaths", "DISEASE", 129, 135], ["coronavirus", "ORGANISM", 9, 20], ["coronavirus disease-2019 (COVID-19", "SPECIES", 9, 43], ["coronavirus disease", "PROBLEM", 9, 28], ["COVID", "TEST", 35, 40], ["coronavirus", "ANATOMY", 9, 20]]], ["Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy.", [["a vaccine", "TREATMENT", 28, 37], ["COVID", "TEST", 63, 68], ["effective pharmacotherapy", "TREATMENT", 111, 136]]], ["To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intravenous (IV) remdesivir was performed.", [["intravenous", "ANATOMY", 118, 129], ["SARS", "DISEASE", 50, 54], ["SARS-CoV-2", "ORGANISM", 50, 60], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 129], ["SARS-CoV", "SPECIES", 50, 58], ["an effective treatment", "TREATMENT", 24, 46], ["SARS", "PROBLEM", 50, 54], ["CoV", "TEST", 55, 58], ["intravenous (IV) remdesivir", "TREATMENT", 118, 145]]], ["Remdesivir, an anti-viral prodrug originally developed to treat Ebola virus disease, has shown broad spectrum activity against the Coronavirus family.", [["Remdesivir", "CHEMICAL", 0, 10], ["Ebola virus disease", "DISEASE", 64, 83], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["Ebola virus", "ORGANISM", 64, 75], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 131, 142], ["Coronavirus family", "PROTEIN", 131, 149], ["Ebola virus", "SPECIES", 64, 75], ["Ebola virus", "SPECIES", 64, 75], ["Remdesivir", "TREATMENT", 0, 10], ["an anti-viral prodrug", "TREATMENT", 12, 33], ["Ebola virus disease", "PROBLEM", 64, 83], ["Ebola virus", "OBSERVATION", 64, 75]]], ["A recent case report reported improvement of clinical symptoms with remdesivir in a patient with COVID-19.", [["remdesivir", "CHEMICAL", 68, 78], ["remdesivir", "CHEMICAL", 68, 78], ["remdesivir", "SIMPLE_CHEMICAL", 68, 78], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["clinical symptoms", "PROBLEM", 45, 62], ["remdesivir", "TREATMENT", 68, 78], ["COVID", "TEST", 97, 102]]], ["Following removal of duplicates (n = 21), eligible studies were reviewed independently by two authors.", [["removal of duplicates", "TREATMENT", 10, 31], ["eligible studies", "TEST", 42, 58]]], ["After the first round of screening, inter-rater agreement was 98.5% (\u03ba = 0.925).", [["screening", "TEST", 25, 34], ["inter-rater agreement", "TEST", 36, 57]]], ["After the second round of full-text screening, inter-rater agreement was 100%.", [["text screening", "TEST", 31, 45], ["inter-rater agreement", "TEST", 47, 68]]], ["A total of seven ongoing and recruiting clinical trials of remdesivir (100-200 milligrams, intravenous [IV]) were included.", [["remdesivir", "CHEMICAL", 59, 69], ["remdesivir", "CHEMICAL", 59, 69], ["remdesivir", "SIMPLE_CHEMICAL", 59, 69], ["remdesivir", "TREATMENT", 59, 69], ["intravenous [IV])", "TREATMENT", 91, 108]]], ["We identified the following primary outcomes: patients discharged (n = 2); time to clinical status improvement (n = 2); improved O2 saturation (n = 2); body temperature normalization (n = 2); and clinical status (n = 1).", [["body", "ANATOMY", 152, 156], ["O2", "CHEMICAL", 129, 131], ["patients", "ORGANISM", 46, 54], ["O2", "SIMPLE_CHEMICAL", 129, 131], ["body", "ORGANISM_SUBDIVISION", 152, 156], ["patients", "SPECIES", 46, 54], ["O2 saturation", "TEST", 129, 142], ["body temperature normalization", "TEST", 152, 182]]], ["Secondary outcomes in all identified studies included documentation of adverse events.", [["adverse events", "PROBLEM", 71, 85]]], ["Therefore, despite supportive data from in vitro and in vivo studies, the clinical effectiveness of IV remdesivir for treatment of COVID-19 and potential side effects remain incompletely defined in the human population.", [["remdesivir", "CHEMICAL", 103, 113], ["COVID-19", "CHEMICAL", 131, 139], ["COVID-19", "CHEMICAL", 131, 139], ["IV remdesivir", "SIMPLE_CHEMICAL", 100, 113], ["human", "ORGANISM", 202, 207], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 202, 207], ["IV remdesivir", "TREATMENT", 100, 113], ["treatment", "TREATMENT", 118, 127], ["COVID", "TEST", 131, 136], ["potential side effects", "PROBLEM", 144, 166]]], ["2020;21(4)737-741.]INTRODUCTIONshare 79.6% sequence identity with SARS-CoV and 96% genome identity with a coronavirus species in bats, its natural reservoir.", [["2020;21(4)737-741", "CHEMICAL", 0, 17], ["coronavirus", "ORGANISM", 106, 117], ["bats", "ORGANISM", 129, 133], ["SARS-CoV", "DNA", 66, 74], ["coronavirus", "SPECIES", 106, 117], ["SARS-CoV", "SPECIES", 66, 74], ["INTRODUCTIONshare", "TREATMENT", 19, 36], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["a coronavirus species", "PROBLEM", 104, 125], ["coronavirus species", "OBSERVATION", 106, 125], ["natural reservoir", "OBSERVATION", 139, 156]]], ["1 Initially referred to as 2019-nCoV, the virus has been renamed SARS-CoV-2, and the disease that results is coronavirus disease-2019 (COVID-19).", [["SARS", "DISEASE", 65, 69], ["coronavirus disease", "DISEASE", 109, 128], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV", "SPECIES", 65, 73], ["the virus", "PROBLEM", 38, 47], ["CoV", "TEST", 70, 73], ["the disease", "PROBLEM", 81, 92], ["coronavirus disease", "PROBLEM", 109, 128], ["COVID", "TEST", 135, 140], ["disease", "OBSERVATION", 85, 92], ["coronavirus disease", "OBSERVATION", 109, 128]]], ["2 At the time of this authorship, there are over 1.6 million confirmed cases and over 99,000 deaths in 205 countries worldwide.", [["deaths", "DISEASE", 93, 99]]], ["3 On March 11, 2020, the World Health Organization responded to the unprecedented spread of COVID-19 and inaction of international governments by Remdesivir for the Treatment of COVID- 19 Musa et al.INTRODUCTIONdeclaring the outbreak a pandemic.", [["Remdesivir", "CHEMICAL", 146, 156], ["COVID", "TEST", 92, 97], ["COVID", "TEST", 178, 183]]], ["4 There is currently no safe and proven treatment for COVID-19 and there is no vaccine for SARS-CoV-2; however, vaccines are under development and several treatments have been proposed and are under investigation.", [["COVID-19", "CHEMICAL", 54, 62], ["SARS", "DISEASE", 91, 95], ["SARS-CoV-2", "ORGANISM", 91, 101], ["SARS-CoV", "SPECIES", 91, 99], ["COVID", "TEST", 54, 59], ["vaccine", "TREATMENT", 79, 86], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99], ["vaccines", "TREATMENT", 112, 120], ["several treatments", "TREATMENT", 147, 165], ["no", "UNCERTAINTY", 21, 23], ["no", "UNCERTAINTY", 76, 78]]], ["[5] [6] The rapid international spread and severity of COVID-19, which causes symptoms varying from fever, dry cough, and shortness of breath to diarrhea and body aches, has spurred the greater scientific community to quickly identify treatments for the disease.", [["body", "ANATOMY", 158, 162], ["COVID-19", "CHEMICAL", 55, 63], ["fever", "DISEASE", 100, 105], ["dry cough", "DISEASE", 107, 116], ["shortness of breath", "DISEASE", 122, 141], ["diarrhea", "DISEASE", 145, 153], ["body aches", "DISEASE", 158, 168], ["body", "ORGANISM_SUBDIVISION", 158, 162], ["The rapid international spread", "PROBLEM", 8, 38], ["COVID", "TEST", 55, 60], ["symptoms", "PROBLEM", 78, 86], ["fever", "PROBLEM", 100, 105], ["dry cough", "PROBLEM", 107, 116], ["shortness of breath", "PROBLEM", 122, 141], ["diarrhea", "PROBLEM", 145, 153], ["body aches", "PROBLEM", 158, 168], ["the disease", "PROBLEM", 250, 261], ["cough", "OBSERVATION", 111, 116], ["disease", "OBSERVATION", 254, 261]]], ["4 Potential pharmacological treatments for COVID-19 may be found in one of three categories: broad-spectrum anti-viral drugs; repurposed existing drugs or substances; and novel therapeutic agents.", [["COVID-19", "CHEMICAL", 43, 51], ["COVID-19", "CHEMICAL", 43, 51], ["COVID-19", "SIMPLE_CHEMICAL", 43, 51], ["Potential pharmacological treatments", "TREATMENT", 2, 38], ["COVID", "TEST", 43, 48], ["broad-spectrum anti-viral drugs", "TREATMENT", 93, 124], ["existing drugs", "TREATMENT", 137, 151], ["substances", "TREATMENT", 155, 165], ["novel therapeutic agents", "TREATMENT", 171, 195], ["anti-viral drugs", "OBSERVATION", 108, 124]]], ["7 We chose to analyze remdesivir based on established inhibition of infection by the novel coronavirus in human cell lines (human liver cancer HuH-7 cells).", [["cell lines", "ANATOMY", 112, 122], ["liver cancer HuH-7 cells", "ANATOMY", 130, 154], ["remdesivir", "CHEMICAL", 22, 32], ["infection", "DISEASE", 68, 77], ["liver cancer", "DISEASE", 130, 142], ["remdesivir", "CHEMICAL", 22, 32], ["coronavirus", "ORGANISM", 91, 102], ["human", "ORGANISM", 106, 111], ["cell lines", "CELL", 112, 122], ["human", "ORGANISM", 124, 129], ["liver cancer HuH-7 cells", "CELL", 130, 154], ["human cell lines", "CELL_LINE", 106, 122], ["human liver cancer HuH-7 cells", "CELL_LINE", 124, 154], ["coronavirus", "SPECIES", 91, 102], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 124, 129], ["remdesivir", "TREATMENT", 22, 32], ["infection", "PROBLEM", 68, 77], ["the novel coronavirus", "PROBLEM", 81, 102], ["human cell lines", "TREATMENT", 106, 122], ["human liver cancer", "PROBLEM", 124, 142], ["HuH", "TEST", 143, 146], ["infection", "OBSERVATION", 68, 77], ["human cell lines", "OBSERVATION", 106, 122], ["liver", "ANATOMY", 130, 135], ["cancer", "OBSERVATION", 136, 142]]], ["8 Remdesivir falls into the first category as an anti-viral prodrug developed to treat infections caused by viruses of the family Filoviridae, which includes Ebola virus (Zaire embolavirus).", [["infections", "DISEASE", 87, 97], ["Ebola virus", "DISEASE", 158, 169], ["Ebola virus", "ORGANISM", 158, 169], ["Zaire embolavirus", "ORGANISM", 171, 188], ["Ebola virus", "SPECIES", 158, 169], ["Zaire embolavirus", "SPECIES", 171, 188], ["Ebola virus", "SPECIES", 158, 169], ["Zaire embolavirus", "SPECIES", 171, 188], ["8 Remdesivir falls", "PROBLEM", 0, 18], ["an anti-viral prodrug", "TREATMENT", 46, 67], ["infections", "PROBLEM", 87, 97], ["the family Filoviridae", "TREATMENT", 119, 141], ["Ebola virus (Zaire embolavirus", "TREATMENT", 158, 188]]], ["9 Discovered in 2016 small molecule GS-5734, remdesivir was used initially to treat Ebola virus disease (EVD) as an adenosine analog that incorporates into viral RNA, leading to premature chain termination and inhibition of viral replication.", [["GS-5734", "CHEMICAL", 36, 43], ["remdesivir", "CHEMICAL", 45, 55], ["Ebola virus disease", "DISEASE", 84, 103], ["EVD", "DISEASE", 105, 108], ["adenosine", "CHEMICAL", 116, 125], ["GS-5734", "CHEMICAL", 36, 43], ["remdesivir", "CHEMICAL", 45, 55], ["adenosine", "CHEMICAL", 116, 125], ["remdesivir", "SIMPLE_CHEMICAL", 45, 55], ["Ebola virus", "ORGANISM", 84, 95], ["adenosine", "SIMPLE_CHEMICAL", 116, 125], ["viral RNA", "RNA", 156, 165], ["Ebola virus", "SPECIES", 84, 95], ["Ebola virus", "SPECIES", 84, 95], ["small molecule GS", "TEST", 21, 38], ["remdesivir", "TREATMENT", 45, 55], ["Ebola virus disease", "PROBLEM", 84, 103], ["EVD", "TREATMENT", 105, 108], ["an adenosine analog", "TREATMENT", 113, 132], ["viral RNA", "PROBLEM", 156, 165], ["premature chain termination", "PROBLEM", 178, 205], ["viral replication", "TREATMENT", 224, 241], ["Ebola virus", "OBSERVATION", 84, 95], ["viral RNA", "OBSERVATION", 156, 165], ["viral replication", "OBSERVATION", 224, 241]]], ["10 But in 2019, the first confirmed case of COVID-19 in the United States prompted the use of intravenous (IV) remdesivir for compassionate use, leading to marked improvement of the patient's clinical status within 24 hours.", [["intravenous", "ANATOMY", 94, 105], ["remdesivir", "CHEMICAL", 111, 121], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 105], ["remdesivir", "SIMPLE_CHEMICAL", 111, 121], ["patient", "ORGANISM", 182, 189], ["patient", "SPECIES", 182, 189], ["COVID", "TEST", 44, 49], ["intravenous (IV) remdesivir", "TREATMENT", 94, 121], ["marked", "OBSERVATION_MODIFIER", 156, 162], ["improvement", "OBSERVATION_MODIFIER", 163, 174]]], ["11 The authors suggested that additional clinical studies were needed to complete the safety and efficacy profiles of the anti-viral drug.", [["additional clinical studies", "TEST", 30, 57], ["the anti-viral drug", "TREATMENT", 118, 137], ["anti-viral drug", "OBSERVATION", 122, 137]]], ["Given the worldwide urgency for an effective and safe treatment for COVID-19 and the therapeutic potential of remdesivir, this systematic review was performed to determine the outcomes and adverse events associated with this investigational, anti-viral medication.METHODSWe performed a systematic review of the use of remdesivir for treatment of COVID-19.", [["remdesivir", "CHEMICAL", 110, 120], ["remdesivir", "CHEMICAL", 318, 328], ["COVID-19", "CHEMICAL", 68, 76], ["remdesivir", "CHEMICAL", 110, 120], ["remdesivir", "CHEMICAL", 318, 328], ["COVID-19", "CHEMICAL", 346, 354], ["remdesivir", "SIMPLE_CHEMICAL", 110, 120], ["remdesivir", "SIMPLE_CHEMICAL", 318, 328], ["the worldwide urgency", "PROBLEM", 6, 27], ["safe treatment", "TREATMENT", 49, 63], ["COVID", "TEST", 68, 73], ["remdesivir", "TREATMENT", 110, 120], ["this systematic review", "TEST", 122, 144], ["adverse events", "PROBLEM", 189, 203], ["this investigational", "TREATMENT", 220, 240], ["anti-viral medication", "TREATMENT", 242, 263], ["remdesivir", "TREATMENT", 318, 328], ["COVID", "TEST", 346, 351]]], ["Eligibile articles included human patients with SARS-CoV-2 infection, remdesivir administration, patient outcomes, and adverse events.", [["SARS-CoV-2 infection", "DISEASE", 48, 68], ["remdesivir", "CHEMICAL", 70, 80], ["human", "ORGANISM", 28, 33], ["patients", "ORGANISM", 34, 42], ["CoV-2", "ORGANISM", 53, 58], ["remdesivir", "SIMPLE_CHEMICAL", 70, 80], ["patient", "ORGANISM", 97, 104], ["human", "SPECIES", 28, 33], ["patients", "SPECIES", 34, 42], ["patient", "SPECIES", 97, 104], ["human", "SPECIES", 28, 33], ["SARS", "PROBLEM", 48, 52], ["CoV", "PROBLEM", 53, 56], ["2 infection", "PROBLEM", 57, 68], ["remdesivir administration", "TREATMENT", 70, 95], ["adverse events", "PROBLEM", 119, 133], ["infection", "OBSERVATION", 59, 68]]], ["A search strategy was developed for each database without restrictions for language or years considered.", [["A search strategy", "TREATMENT", 0, 17]]], ["The search parameters for Embase were as follows:METHODS(1) remdesivir OR GS-5734 Eligible studies were identified and screened according to inclusion-exclusion criteria that were established a priori (Table 1) .", [["GS", "TEST", 74, 76], ["Eligible studies", "TEST", 82, 98]]], ["Studies that meet any of the exclusion criteria should be excluded from the systematic review.Musa et al.Remdesivir for the Treatment of COVID-19Musa et al.was quantified by Cohen's kappa scores as well as percentage agreement as recommended by McHugh.", [["Remdesivir", "CHEMICAL", 105, 115], ["Studies", "TEST", 0, 7], ["Remdesivir", "TREATMENT", 105, 115], ["COVID", "TREATMENT", 137, 142]]], ["Data were extracted by one author and included the following items: type of study; intervention; number of participants; patient outcomes; adverse events; and study characteristics.", [["patient", "ORGANISM", 121, 128], ["participants", "SPECIES", 107, 119], ["patient", "SPECIES", 121, 128], ["intervention", "TREATMENT", 83, 95], ["adverse events", "PROBLEM", 139, 153], ["study characteristics", "TEST", 159, 180]]], ["13 There is no online review protocol for this study.RESULTSThe database search yielded a total of 86 items from the following databases: Embase (n = 21), PubMed (n = 20), Web of Science (n = 28), European Union Clinical Trials Register (n = 2), and clinicaltrials.gov (n = 8).", [["this study", "TEST", 42, 52], ["no", "UNCERTAINTY", 12, 14]]], ["After removal of duplicates (n = 21), the first round of screening yielded eight potentially eligible items.", [["removal of duplicates", "TREATMENT", 6, 27], ["screening", "TEST", 57, 66]]], ["Studies were excluded for meeting any of the following criteria: non-human study (n = 3); review or metaanalysis (n = 15); not including SARS-CoV-2 (n = 16); or multiple criteria met (n = 23).", [["SARS", "DISEASE", 137, 141], ["Studies", "TEST", 0, 7], ["non-human study", "TEST", 65, 80], ["metaanalysis", "TEST", 100, 112], ["SARS", "TEST", 137, 141], ["CoV", "TEST", 142, 145]]], ["Inter-rater agreement following the first round of screening was 98.5% (\u03ba = 0.925).", [["screening", "TEST", 51, 60]]], ["After the second round of screening, seven items were included.", [["screening", "TEST", 26, 35]]], ["Interrater agreement was 100%.", [["Interrater agreement", "TEST", 0, 20]]], ["Study characteristics are described in Table 2 .RESULTSThis review of remdesivir identified ongoing and recruiting trials in 11 countries, including the United States, China, Taiwan, France, and Italy.", [["Study characteristics", "TEST", 0, 21]]], ["The average number of participants was 450 (range = 308-600).", [["participants", "SPECIES", 22, 34], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["Selection criteria for each trial varied according to the severity of symptoms (based on peripheral capillary oxygen saturation).", [["peripheral capillary", "ANATOMY", 89, 109], ["oxygen", "CHEMICAL", 110, 116], ["oxygen", "CHEMICAL", 110, 116], ["peripheral capillary", "MULTI-TISSUE_STRUCTURE", 89, 109], ["oxygen", "SIMPLE_CHEMICAL", 110, 116], ["Selection criteria", "TEST", 0, 18], ["symptoms", "PROBLEM", 70, 78], ["peripheral capillary oxygen saturation", "TEST", 89, 127]]], ["Five trials involved a 200-milligram (mg) intravenous (IV) loading dose following by maintenance dose of 100 mg for nine days.", [["intravenous", "ANATOMY", 42, 53], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 53], ["intravenous (IV) loading dose", "TREATMENT", 42, 71]]], ["Two trials involved a single, 100-mg IV infusion.", [["IV infusion", "TREATMENT", 37, 48]]], ["The primary outcomes for each trial were as follows: proportion of patients discharged (n = 2); time to clinical improvement (n = 2); improved oxygen saturation (n = 2); normalization of body temperature (n = 2); and percentage of each severity rating on a 7-point ordinal scale to assess clinical status (n = 1).", [["body", "ANATOMY", 187, 191], ["oxygen", "CHEMICAL", 143, 149], ["oxygen", "CHEMICAL", 143, 149], ["patients", "ORGANISM", 67, 75], ["oxygen", "SIMPLE_CHEMICAL", 143, 149], ["body", "ORGANISM_SUBDIVISION", 187, 191], ["patients", "SPECIES", 67, 75], ["oxygen saturation", "TEST", 143, 160], ["body temperature", "TEST", 187, 203], ["each severity rating", "PROBLEM", 231, 251]]], ["Secondary outcomes included adverse events (n = 7); length of stay (n = 2); mortality (n = 3); duration of ventilation or supplemental oxygen use (n = 3); and reduction in viral load (n = 2).", [["oxygen", "CHEMICAL", 135, 141], ["oxygen", "CHEMICAL", 135, 141], ["oxygen", "SIMPLE_CHEMICAL", 135, 141], ["adverse events", "PROBLEM", 28, 42], ["ventilation", "TREATMENT", 107, 118], ["supplemental oxygen use", "TREATMENT", 122, 145], ["viral load", "TEST", 172, 182], ["viral load", "OBSERVATION", 172, 182]]], ["All seven of the included studies were Phase 3 clinical trials that were either recruiting patients or considered ongoing.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["In each trial, IV remdesivir (100-200 mg) was the primary intervention.", [["remdesivir", "CHEMICAL", 18, 28], ["remdesivir", "CHEMICAL", 18, 28], ["remdesivir", "SIMPLE_CHEMICAL", 18, 28], ["IV remdesivir", "TREATMENT", 15, 28], ["the primary intervention", "TREATMENT", 46, 70]]], ["The predominant treatment protocol described a 200 mg dose administered on the first day followed by subsequent doses of 100 mg each following day (for a total of 5 or 10 days depending on the treatment arm).DISCUSSIONHowever, none of the included studies have reported completed or partial data.", [["The predominant treatment protocol", "TREATMENT", 0, 34], ["the treatment arm", "TREATMENT", 189, 206], ["partial data", "TEST", 283, 295]]], ["As a result, the clinical utility of remdesivir for the treatment of COVID-19 remains to be seen, and any adverse events have yet to be reported.DISCUSSIONAs early as 2017, Sheahan et al reported GS-5734 activity against MERS-CoV and SARS-CoV in human lung cells, suggesting that remdesivir may prove effective against endemic and emerging coronaviruses.", [["lung cells", "ANATOMY", 252, 262], ["remdesivir", "CHEMICAL", 37, 47], ["GS-5734", "CHEMICAL", 196, 203], ["SARS", "DISEASE", 234, 238], ["remdesivir", "CHEMICAL", 280, 290], ["coronaviruses", "DISEASE", 340, 353], ["remdesivir", "CHEMICAL", 37, 47], ["COVID-19", "CHEMICAL", 69, 77], ["remdesivir", "CHEMICAL", 280, 290], ["remdesivir", "SIMPLE_CHEMICAL", 37, 47], ["GS-5734", "SIMPLE_CHEMICAL", 196, 203], ["MERS-CoV", "ORGANISM", 221, 229], ["SARS-CoV", "ORGANISM", 234, 242], ["human", "ORGANISM", 246, 251], ["lung cells", "CELL", 252, 262], ["remdesivir", "SIMPLE_CHEMICAL", 280, 290], ["coronaviruses", "ORGANISM", 340, 353], ["human lung cells", "CELL_TYPE", 246, 262], ["human", "SPECIES", 246, 251], ["MERS-CoV", "SPECIES", 221, 229], ["SARS-CoV", "SPECIES", 234, 242], ["human", "SPECIES", 246, 251], ["remdesivir", "TREATMENT", 37, 47], ["COVID", "TEST", 69, 74], ["any adverse events", "PROBLEM", 102, 120], ["GS", "TEST", 196, 198], ["MERS", "PROBLEM", 221, 225], ["CoV", "PROBLEM", 226, 229], ["SARS", "PROBLEM", 234, 238], ["CoV in human lung cells", "PROBLEM", 239, 262], ["endemic", "PROBLEM", 319, 326], ["emerging coronaviruses", "PROBLEM", 331, 353], ["lung", "ANATOMY", 252, 256]]], ["14 Agostini et al later reported that GS-5734 effectively inhibited coronavirus replication in vivo despite intact exoribonuclease proofreading, indicating that remdesivir may have utility against resistant coronavirus strains.", [["GS-5734", "CHEMICAL", 38, 45], ["remdesivir", "CHEMICAL", 161, 171], ["coronavirus", "DISEASE", 207, 218], ["GS-5734", "CHEMICAL", 38, 45], ["remdesivir", "CHEMICAL", 161, 171], ["GS-5734", "SIMPLE_CHEMICAL", 38, 45], ["coronavirus", "ORGANISM", 68, 79], ["exoribonuclease", "GENE_OR_GENE_PRODUCT", 115, 130], ["remdesivir", "SIMPLE_CHEMICAL", 161, 171], ["coronavirus strains", "ORGANISM", 207, 226], ["exoribonuclease", "PROTEIN", 115, 130], ["coronavirus", "SPECIES", 68, 79], ["coronavirus", "SPECIES", 68, 79], ["GS", "TEST", 38, 40], ["coronavirus replication", "TREATMENT", 68, 91], ["intact exoribonuclease proofreading", "TREATMENT", 108, 143], ["resistant coronavirus strains", "PROBLEM", 197, 226]]], ["15 Further research has demonstrated the broad-spectrum activity of remdesivir for the purpose of treating endemic coronavirus infections.", [["remdesivir", "CHEMICAL", 68, 78], ["coronavirus infections", "DISEASE", 115, 137], ["remdesivir", "CHEMICAL", 68, 78], ["remdesivir", "SIMPLE_CHEMICAL", 68, 78], ["coronavirus", "ORGANISM", 115, 126], ["remdesivir", "TREATMENT", 68, 78], ["endemic coronavirus infections", "PROBLEM", 107, 137], ["coronavirus infections", "OBSERVATION", 115, 137]]], ["16 In December 2019, the first case of SARS-CoV-2 in the United States was successfully treated by IV remdesivir without adverse effects.", [["SARS", "DISEASE", 39, 43], ["remdesivir", "CHEMICAL", 102, 112], ["remdesivir", "SIMPLE_CHEMICAL", 102, 112], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "PROBLEM", 39, 43], ["CoV", "TEST", 44, 47], ["IV remdesivir", "TREATMENT", 99, 112], ["adverse effects", "PROBLEM", 121, 136]]], ["11 The patient was treated with remdesivir on hospital day 7, and on day 8 the patient experienced symptomatic and clinical improvement significant enough to discontinue supplemental oxygenation with improved saturation in room air, as well as resolution of rales and anorexia.", [["remdesivir", "CHEMICAL", 32, 42], ["anorexia", "DISEASE", 268, 276], ["remdesivir", "CHEMICAL", 32, 42], ["patient", "ORGANISM", 7, 14], ["remdesivir", "SIMPLE_CHEMICAL", 32, 42], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 7, 14], ["patient", "SPECIES", 79, 86], ["remdesivir", "TREATMENT", 32, 42], ["supplemental oxygenation", "TREATMENT", 170, 194], ["rales", "PROBLEM", 258, 263], ["anorexia", "PROBLEM", 268, 276], ["rales", "OBSERVATION", 258, 263], ["anorexia", "OBSERVATION", 268, 276]]], ["Remdesivir was first reported for treatment of EVD in 2016 with subsequent studies indicating mixed results.", [["Remdesivir", "CHEMICAL", 0, 10], ["EVD", "DISEASE", 47, 50], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["Remdesivir", "TREATMENT", 0, 10], ["EVD", "TREATMENT", 47, 50], ["subsequent studies", "TEST", 64, 82]]], ["10, [17] [18] Ko et al argued that the findings from previous studies of remdesivir for EVD support testing of remdesivir for treatment of COVID-19.", [["remdesivir", "CHEMICAL", 73, 83], ["remdesivir", "CHEMICAL", 111, 121], ["remdesivir", "CHEMICAL", 73, 83], ["remdesivir", "CHEMICAL", 111, 121], ["COVID-19", "CHEMICAL", 139, 147], ["remdesivir", "SIMPLE_CHEMICAL", 73, 83], ["remdesivir", "SIMPLE_CHEMICAL", 111, 121], ["previous studies", "TEST", 53, 69], ["remdesivir", "TREATMENT", 73, 83], ["EVD support testing", "TEST", 88, 107], ["remdesivir", "TREATMENT", 111, 121], ["COVID", "TEST", 139, 144]]], ["19 Concurrent in vitro research has supported the use of the drug to treat SARS-CoV-2 infections.", [["SARS-CoV-2 infections", "DISEASE", 75, 96], ["SARS-CoV-2", "ORGANISM", 75, 85], ["SARS-CoV", "SPECIES", 75, 83], ["the drug", "TREATMENT", 57, 65], ["SARS", "PROBLEM", 75, 79], ["CoV-2 infections", "PROBLEM", 80, 96]]], ["20 In contrast, Zhang et al have raised concerns about the possibility of unknown adverse reactions.", [["unknown adverse reactions", "PROBLEM", 74, 99]]], ["8LIMITATIONSThe primary limitation of this systematic review stems from the lack of reported patient outcomes from human trials, which are in varying phases of completion.", [["patient", "ORGANISM", 93, 100], ["human", "ORGANISM", 115, 120], ["patient", "SPECIES", 93, 100], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120], ["human trials", "TEST", 115, 127]]], ["Although some clinical trial registries display preliminary reports of ongoing trials, these partial data are not available for quantitative analysis.", [["ongoing trials", "TREATMENT", 71, 85], ["these partial data", "TEST", 87, 105], ["quantitative analysis", "TEST", 128, 149]]], ["Trials are scheduled to be completed as early as April-May 2020.CONCLUSIONThere is both in vitro and limited clinical evidence that supports the use of remdesivir to treat SARS-CoV-2.", [["remdesivir", "CHEMICAL", 152, 162], ["SARS", "DISEASE", 172, 176], ["remdesivir", "CHEMICAL", 152, 162], ["remdesivir", "SIMPLE_CHEMICAL", 152, 162], ["CoV-2", "ORGANISM", 177, 182], ["SARS-CoV", "SPECIES", 172, 180], ["remdesivir", "TREATMENT", 152, 162], ["SARS", "PROBLEM", 172, 176], ["CoV", "TEST", 177, 180]]], ["However, Phase 3 clinical trials have not yet been completed and partial data has not yet been reported.", [["partial data", "TEST", 65, 77]]], ["The side-effects profile of remdesivir remains similarly not well defined.", [["remdesivir", "CHEMICAL", 28, 38], ["remdesivir", "CHEMICAL", 28, 38], ["remdesivir", "SIMPLE_CHEMICAL", 28, 38]]], ["Until high-quality studies report significant improvements with administration of IV remdesivir, the use of this experimental drug should be limited to randomized controlled trials.", [["remdesivir", "CHEMICAL", 85, 95], ["remdesivir", "CHEMICAL", 85, 95], ["IV remdesivir", "TREATMENT", 82, 95], ["this experimental drug", "TREATMENT", 108, 130], ["randomized controlled trials", "TREATMENT", 152, 180]]], ["Therefore, the potential of remdesivir as a standard of care therapy for COVID-19 remains to be determined.NOTE:An addenum to this article has been written by the author AM.", [["remdesivir", "CHEMICAL", 28, 38], ["remdesivir", "CHEMICAL", 28, 38], ["COVID-19", "CHEMICAL", 73, 81], ["remdesivir", "SIMPLE_CHEMICAL", 28, 38], ["remdesivir", "TREATMENT", 28, 38], ["care therapy", "TREATMENT", 56, 68], ["COVID", "TREATMENT", 73, 78]]], ["20 Remdesivir for the Treatment of COVID- 19 Musa et al.", [["Remdesivir", "CHEMICAL", 3, 13], ["COVID", "TEST", 35, 40]]]], "PMC7498470": [["The global response to limit the spread of COVID-19 has diverted attention and resources from existing local health priorities, particularly in countries of low and middle income (LMICs).1 As highlighted in a Comment in The Lancet Gastroenterology & Hepatology by Neil Gupta and colleagues,2 the collateral damage on efforts to address the viral hepatitis epidemic in sub-Saharan Africa is of high concern.", [["COVID-19", "CHEMICAL", 43, 51], ["collateral damage", "DISEASE", 296, 313], ["viral hepatitis", "DISEASE", 340, 355], ["COVID", "TEST", 43, 48], ["low and middle income (LMICs", "TREATMENT", 157, 185], ["the collateral damage", "PROBLEM", 292, 313], ["the viral hepatitis epidemic", "PROBLEM", 336, 364], ["global", "OBSERVATION_MODIFIER", 4, 10], ["response", "OBSERVATION_MODIFIER", 11, 19], ["viral", "OBSERVATION_MODIFIER", 340, 345], ["hepatitis", "OBSERVATION", 346, 355]]], ["However, the potential effect of COVID-19 on viral hepatitis services has been poorly documented.2", [["COVID-19", "CHEMICAL", 33, 41], ["viral hepatitis", "DISEASE", 45, 60], ["COVID-19", "CHEMICAL", 33, 41], ["COVID-19", "GENE_OR_GENE_PRODUCT", 33, 41], ["COVID", "TEST", 33, 38], ["viral hepatitis services", "TREATMENT", 45, 69]]]], "3c79635413dd3ad92d2d86936fa79919c92eef2a": [["This is because of the danger of new bacteria is high.", [["new bacteria", "PROBLEM", 33, 45], ["new", "OBSERVATION_MODIFIER", 33, 36], ["bacteria", "OBSERVATION", 37, 45], ["high", "OBSERVATION_MODIFIER", 49, 53]]], ["It is mostly MRSA (methicillin-resistant Staphylococcus aureus), C. diff.", [["MRSA", "CHEMICAL", 13, 17], ["methicillin", "CHEMICAL", 19, 30], ["Staphylococcus aureus", "DISEASE", 41, 62], ["methicillin", "CHEMICAL", 19, 30], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 19, 62], ["MRSA", "SPECIES", 13, 17], ["Staphylococcus aureus", "SPECIES", 41, 62], ["Staphylococcus aureus", "SPECIES", 41, 62], ["MRSA", "PROBLEM", 13, 17], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 19, 62], ["C. diff", "PROBLEM", 65, 72], ["mostly", "OBSERVATION_MODIFIER", 6, 12], ["MRSA", "OBSERVATION", 13, 17], ["Staphylococcus aureus", "OBSERVATION", 41, 62]]], ["(Clostridium difficile), VRE (Vancomycin-resistant enterococci) and of new pathogens such as MERS (respiratory syndrome).", [["Clostridium difficile", "DISEASE", 1, 22], ["VRE", "CHEMICAL", 25, 28], ["Vancomycin", "CHEMICAL", 30, 40], ["MERS (respiratory syndrome", "DISEASE", 93, 119], ["Vancomycin", "CHEMICAL", 30, 40], ["Clostridium difficile", "ORGANISM", 1, 22], ["Vancomycin", "SIMPLE_CHEMICAL", 30, 40], ["Clostridium difficile", "SPECIES", 1, 22], ["Clostridium difficile", "SPECIES", 1, 22], ["Clostridium difficile)", "PROBLEM", 1, 23], ["VRE", "PROBLEM", 25, 28], ["Vancomycin", "TREATMENT", 30, 40], ["resistant enterococci", "PROBLEM", 41, 62], ["new pathogens", "PROBLEM", 71, 84], ["MERS (respiratory syndrome", "PROBLEM", 93, 119], ["new", "OBSERVATION_MODIFIER", 71, 74], ["pathogens", "OBSERVATION", 75, 84], ["respiratory syndrome", "OBSERVATION", 99, 119]]], ["These microorganisms are resistant to antibiotics, and commonly referred to as \"superbugs\".", [["antibiotics", "TREATMENT", 38, 49], ["resistant", "OBSERVATION_MODIFIER", 25, 34]]], ["As a result of infection by these pathogens often involve considerable pain and suffering and many deaths.", [["infection", "DISEASE", 15, 24], ["pain", "DISEASE", 71, 75], ["deaths", "DISEASE", 99, 105], ["infection", "PROBLEM", 15, 24], ["these pathogens", "PROBLEM", 28, 43], ["considerable pain", "PROBLEM", 58, 75], ["infection", "OBSERVATION", 15, 24]]], ["These infections are major problems and significant costs of modern health sector.", [["infections", "DISEASE", 6, 16], ["These infections", "PROBLEM", 0, 16], ["major problems", "PROBLEM", 21, 35], ["infections", "OBSERVATION", 6, 16], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["costs", "OBSERVATION_MODIFIER", 52, 57]]], ["Cleaning and disinfection are expensive and are not effective enough due to inaccessible areas.", [["Cleaning", "TREATMENT", 0, 8], ["disinfection", "TREATMENT", 13, 25], ["inaccessible areas", "PROBLEM", 76, 94], ["disinfection", "OBSERVATION", 13, 25]]], ["Since there is no way to force people to disinfect hands remains to introduce robots to disinfect [1] .IntroductionThe robots, which will be described in this paper is an attempt to reduce the risk of hospital infections.", [["infections", "DISEASE", 210, 220], ["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37], ["IntroductionThe robots", "TREATMENT", 103, 125], ["hospital infections", "PROBLEM", 201, 220], ["no way", "UNCERTAINTY", 15, 21]]], ["There are many ways of transmitting infections, and studies have shown that the greatest cause of contact surface such as: remote control, door handles or cabinets, a button to call for help, etc. UV-C disinfection robot provides an economical and effective measure in limiting the spread of bacteria.", [["surface", "ANATOMY", 106, 113], ["infections", "DISEASE", 36, 46], ["UV-C", "CHEMICAL", 197, 201], ["surface", "CELLULAR_COMPONENT", 106, 113], ["transmitting infections", "PROBLEM", 23, 46], ["studies", "TEST", 52, 59], ["UV", "TREATMENT", 197, 199], ["C disinfection robot", "TREATMENT", 200, 220], ["an economical", "TREATMENT", 230, 243], ["bacteria", "PROBLEM", 292, 300], ["infections", "OBSERVATION", 36, 46]]], ["When bacteria are exposed to UV-C light of their DNA absorbs light energy and causes cell damage that prevents new infecting others.", [["cell", "ANATOMY", 85, 89], ["UV-C", "CHEMICAL", 29, 33], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["cell", "CELL", 85, 89], ["bacteria", "PROBLEM", 5, 13], ["UV", "TREATMENT", 29, 31], ["cell damage", "PROBLEM", 85, 96], ["cell damage", "OBSERVATION", 85, 96], ["new", "OBSERVATION_MODIFIER", 111, 114], ["infecting", "OBSERVATION_MODIFIER", 115, 124]]], ["The robot is controlled by the medical staff and the time for which disinfect a room is 10-15 min depending on the size of the room.", [["robot", "OBSERVATION", 4, 9]]], ["When operating the robot nobody should be present in the room because the UV-C light damages eyesight and adversely affects organism people.IntroductionStudies have shown that this method of disinfection kills more than 70% of bacteria compared to the traditional way, so it is necessary to introduce these robots in hospital for prevention, reducing the spread of infections and reduce the cost of treatment of the same.UV LightUV-C has been a proven technology for disinfecting air, water and instruments for over a century.", [["UV-C", "CHEMICAL", 74, 78], ["infections", "DISEASE", 365, 375], ["UV-C", "CHEMICAL", 429, 433], ["people", "ORGANISM", 133, 139], ["people", "SPECIES", 133, 139], ["disinfection", "TREATMENT", 191, 203], ["bacteria", "PROBLEM", 227, 235], ["these robots", "TREATMENT", 301, 313], ["prevention", "TREATMENT", 330, 340], ["infections", "PROBLEM", 365, 375], ["treatment", "TREATMENT", 399, 408], ["disinfecting air, water and instruments", "TREATMENT", 467, 506], ["infections", "OBSERVATION", 365, 375]]], ["Niels Finsen was awarded the Nobel Prize for Medicine in 1903 for being the first to use \"light therapy\" to treat disease with direct disinfection of skin.", [["skin", "ANATOMY", 150, 154], ["skin", "ORGAN", 150, 154], ["light therapy", "TREATMENT", 90, 103], ["disease", "PROBLEM", 114, 121], ["direct disinfection of skin", "TREATMENT", 127, 154], ["skin", "ANATOMY", 150, 154]]], ["By the 1930s, UV had come into common use throughout hospitals for air and water treatment and by WWII, UV was in widespread use in processing plants, water treatment facilities, and anywhere microbial contamination was a concern.", [["UV", "CHEMICAL", 104, 106], ["air and water treatment", "TREATMENT", 67, 90], ["water treatment facilities", "TREATMENT", 151, 177], ["anywhere microbial contamination", "PROBLEM", 183, 215]]], ["UV gained fame in the 1950s for helping to eradicate TB before fading in use in the 1960s with the proliferation of antibiotics and chemical disinfectants [2, 3] .", [["TB", "DISEASE", 53, 55], ["TB", "PROBLEM", 53, 55], ["antibiotics", "TREATMENT", 116, 127], ["chemical disinfectants", "TREATMENT", 132, 154]]], ["Now with the current focus on solving the crisis of rising multidrug resistant organisms (MDROs), healthcare acquired infections (HAIs), and treatment costs, UV has once again risen to the top of the list in the war against superbugs.", [["MDROs", "DISEASE", 90, 95], ["infections", "DISEASE", 118, 128], ["HAIs", "DISEASE", 130, 134], ["UV", "CHEMICAL", 158, 160], ["superbugs", "DISEASE", 224, 233], ["rising multidrug resistant organisms", "PROBLEM", 52, 88], ["healthcare acquired infections", "PROBLEM", 98, 128], ["treatment costs", "TREATMENT", 141, 156], ["UV", "TREATMENT", 158, 160], ["rising", "OBSERVATION_MODIFIER", 52, 58], ["multidrug resistant", "OBSERVATION_MODIFIER", 59, 78]]], ["After 100 years in healthcare use, UV has found a new application in hospitals providing surface disinfection of patient rooms, bathrooms, operating rooms (ORs), equipment rooms, and mobile devices [4] .UV LightThe sun is by far the strongest source of ultraviolet radiation in our environment.", [["surface", "ANATOMY", 89, 96], ["UV", "CHEMICAL", 35, 37], ["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120], ["mobile devices", "TREATMENT", 183, 197], ["UV", "TREATMENT", 203, 205], ["ultraviolet radiation", "TREATMENT", 253, 274], ["new", "OBSERVATION_MODIFIER", 50, 53]]], ["Solar emissions include visible light, heat and ultraviolet (UV) radiation.", [["Solar emissions", "TREATMENT", 0, 15], ["ultraviolet (UV) radiation", "TREATMENT", 48, 74]]], ["Just as visible light consists of different colours that become apparent in a rainbow, the UV radiation spectrum is divided into three regions called UVA, UVB and UVC.", [["UVA", "CHEMICAL", 150, 153], ["UVB", "CHEMICAL", 155, 158], ["UVC", "CHEMICAL", 163, 166], ["UVA", "SIMPLE_CHEMICAL", 150, 153], ["UVB", "SIMPLE_CHEMICAL", 155, 158], ["different colours", "PROBLEM", 34, 51], ["the UV radiation spectrum", "TREATMENT", 87, 112], ["UVB", "TREATMENT", 155, 158], ["UVC", "TREATMENT", 163, 166], ["different colours", "OBSERVATION_MODIFIER", 34, 51], ["UVA", "OBSERVATION", 150, 153], ["UVC", "ANATOMY", 163, 166]]], ["As sunlight passes through the atmosphere, all UVC and most UVB is absorbed by ozone, water vapour, oxygen and carbon dioxide.", [["UVC", "CHEMICAL", 47, 50], ["UVB", "CHEMICAL", 60, 63], ["ozone", "CHEMICAL", 79, 84], ["oxygen", "CHEMICAL", 100, 106], ["carbon dioxide", "CHEMICAL", 111, 125], ["ozone", "CHEMICAL", 79, 84], ["oxygen", "CHEMICAL", 100, 106], ["carbon dioxide", "CHEMICAL", 111, 125], ["UVB", "SIMPLE_CHEMICAL", 60, 63], ["ozone", "SIMPLE_CHEMICAL", 79, 84], ["water", "SIMPLE_CHEMICAL", 86, 91], ["oxygen", "SIMPLE_CHEMICAL", 100, 106], ["carbon dioxide", "SIMPLE_CHEMICAL", 111, 125], ["the atmosphere", "TREATMENT", 27, 41], ["all UVC", "TREATMENT", 43, 50], ["most UVB", "TREATMENT", 55, 63], ["water vapour", "TREATMENT", 86, 98], ["oxygen", "TREATMENT", 100, 106], ["carbon dioxide", "TREATMENT", 111, 125], ["UVC", "OBSERVATION", 47, 50], ["most UVB", "OBSERVATION_MODIFIER", 55, 63]]], ["UVA is not filtered as significantly by the atmosphere.UV LightParticularly at wavelengths around 260-270 nm, UV breaks molecular bonds within microorganismal DNA, producing thymine dimers that can kill or disable the organisms [3].UV Light\u2022 Mercury-based lamps emit UV light at the 253.7 nm line.UV Light\u2022 Ultraviolet Light Emitting Diodes (UV-C LED) lamps emit UV light at selectable wavelengths between 255 and 280 nm. \u2022 Pulsed-xenon lamps emit UV light across the entire UV spectrum with a peak emission near 230 nm [3] (Fig. 1 ).UV LightThe relatively long-wavelength UVA accounts for approximately 95% of the UV radiation reaching the Earth's surface.", [["surface", "ANATOMY", 649, 656], ["UVA", "CHEMICAL", 0, 3], ["thymine", "CHEMICAL", 174, 181], ["Mercury", "CHEMICAL", 242, 249], ["UV-C", "CHEMICAL", 342, 346], ["UVA", "CHEMICAL", 573, 576], ["thymine", "CHEMICAL", 174, 181], ["Mercury", "CHEMICAL", 242, 249], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["thymine dimers", "SIMPLE_CHEMICAL", 174, 188], ["surface", "CELLULAR_COMPONENT", 649, 656], ["microorganismal DNA", "DNA", 143, 162], ["UVA", "TREATMENT", 0, 3], ["UV", "TREATMENT", 55, 57], ["UV breaks molecular bonds", "PROBLEM", 110, 135], ["microorganismal DNA", "PROBLEM", 143, 162], ["thymine dimers", "PROBLEM", 174, 188], ["UV", "TREATMENT", 297, 299], ["Ultraviolet Light Emitting Diodes (UV-C LED) lamps", "TREATMENT", 307, 357], ["Pulsed", "TEST", 424, 430], ["xenon lamps", "TREATMENT", 431, 442], ["a peak emission", "TEST", 492, 507], ["UV", "TREATMENT", 534, 536], ["The relatively long-wavelength UVA", "TREATMENT", 542, 576], ["the UV radiation", "TREATMENT", 611, 627], ["not", "UNCERTAINTY", 7, 10], ["filtered", "OBSERVATION", 11, 19], ["molecular bonds", "OBSERVATION", 120, 135], ["Mercury", "OBSERVATION_MODIFIER", 242, 249], ["UV radiation", "OBSERVATION", 615, 627]]], ["It can penetrate into the deeper layers of the skin and is responsible for the immediate tanning effect.", [["skin", "ANATOMY", 47, 51], ["layers", "TISSUE", 33, 39], ["skin", "ORGAN", 47, 51], ["deeper", "ANATOMY_MODIFIER", 26, 32], ["layers", "ANATOMY_MODIFIER", 33, 39], ["skin", "ANATOMY", 47, 51]]], ["Furthermore, it also contributes to skin ageing and wrinkling.", [["skin", "ANATOMY", 36, 40], ["skin", "ORGAN", 36, 40], ["wrinkling", "PROBLEM", 52, 61], ["skin", "ANATOMY", 36, 40], ["ageing", "OBSERVATION", 41, 47], ["wrinkling", "OBSERVATION", 52, 61]]], ["For a long time it was thought that UVA could not cause any lasting damage.", [["UVA", "CHEMICAL", 36, 39], ["UVA", "SIMPLE_CHEMICAL", 36, 39], ["UVA", "TREATMENT", 36, 39], ["any lasting damage", "PROBLEM", 56, 74]]], ["Recent studies strongly suggest that it may also enhance the development of skin cancers.Service Robots in MedicineRobots have broad application in healthcare.", [["skin cancers", "ANATOMY", 76, 88], ["skin cancers", "DISEASE", 76, 88], ["skin cancers", "CANCER", 76, 88], ["Recent studies", "TEST", 0, 14], ["skin cancers", "PROBLEM", 76, 88], ["skin", "ANATOMY", 76, 80], ["cancers", "OBSERVATION", 81, 88]]], ["Such robots include roving machines mounted with ipads to provide physician tele-presence, surgical assistance robots such as the Da Vinci system, drones for delivery of emergency or other medical equipment, assistive and therapeutic robotic devices used to increase the individual's capability or rehabilitate, empathic robots used in the care of the older or physically/mentally limited individual, and industrial robots such as those used to sterilize patient rooms or for supply delivery.", [["patient", "ORGANISM", 455, 462], ["patient", "SPECIES", 455, 462], ["roving machines", "TREATMENT", 20, 35], ["surgical assistance robots", "TREATMENT", 91, 117], ["other medical equipment", "TREATMENT", 183, 206], ["assistive and therapeutic robotic devices", "TREATMENT", 208, 249], ["empathic robots", "TREATMENT", 312, 327], ["industrial robots", "TREATMENT", 405, 422], ["supply delivery", "TREATMENT", 476, 491]]], ["Other robots are in research and development stage now and still other applications of robotics in healthcare are being considered for the future.", [["Other robots", "TREATMENT", 0, 12], ["robotics in healthcare", "TREATMENT", 87, 109]]], ["Robots, already, have wide-ranging healthcare applications within surgery, ambulation in the disabled, hospital operations, neuro-muscular rehabilitation, and emotional care and aging care, to name a few.", [["surgery", "TREATMENT", 66, 73], ["hospital operations", "TREATMENT", 103, 122], ["neuro-muscular rehabilitation", "TREATMENT", 124, 153], ["emotional care", "TREATMENT", 159, 173]]], ["Robust, exciting research of new applications of robotics in healthcare is thriving [5] .Service Robots in MedicineAs robots take care of our more intimate needs, such as personal caregiving, human to robot and robot to human interactions will become a central focus of study and philosophical discussion.", [["human", "ORGANISM", 192, 197], ["human", "ORGANISM", 220, 225], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 220, 225], ["new applications of robotics", "TREATMENT", 29, 57], ["new", "OBSERVATION_MODIFIER", 29, 32]]], ["Comfort with robots may depend on multiple variables, such as the individual, culture, particular application, or industry.", [["robots", "TREATMENT", 13, 19], ["culture", "TEST", 78, 85]]], ["Trust is at the core of the use of autonomous robots in healthcare, and safety must be proven [7] .Service Robots in MedicineOnce the qualifications of optimal design, answered needs, safety, and trust are met, \"the sky is the limit\" for robots and robotics in health [5]!Service Robots for DisinfectionTo solve the hospital disinfection problem, several design requirements had to be imposed.", [["autonomous robots", "TREATMENT", 35, 52], ["Disinfection", "TREATMENT", 291, 303]]], ["There are a myriad of design requirements for a commercial robotic disinfector and even more if the robot is to operate in a hospital.", [["a commercial robotic disinfector", "TREATMENT", 46, 78], ["myriad", "OBSERVATION_MODIFIER", 12, 18]]], ["The robot produces UV light in a hospital room and in 5 min it can drastically reduce the germs in room [8] (Fig. 3) .Service Robots for DisinfectionThe device is run when the room is empty after a patient discharge and terminal cleaning.", [["patient", "ORGANISM", 198, 205], ["patient", "SPECIES", 198, 205], ["The device", "TREATMENT", 149, 159], ["terminal cleaning", "TREATMENT", 220, 237], ["empty", "OBSERVATION", 184, 189]]], ["The xenon bulb in the device will pulse for 5 min disinfecting an area around the device.", [["xenon", "CHEMICAL", 4, 9], ["xenon", "CHEMICAL", 4, 9], ["xenon bulb", "MULTI-TISSUE_STRUCTURE", 4, 14], ["The xenon bulb", "TREATMENT", 0, 14], ["the device", "TREATMENT", 18, 28], ["the device", "TREATMENT", 78, 88], ["xenon", "OBSERVATION_MODIFIER", 4, 9], ["bulb", "OBSERVATION_MODIFIER", 10, 14], ["area", "OBSERVATION_MODIFIER", 66, 70], ["device", "OBSERVATION", 82, 88]]], ["UVC light cannot go through safety glasses, walls or windows.", [["UVC", "CHEMICAL", 0, 3], ["UVC light", "TREATMENT", 0, 9]]], ["However with prolonged exposure UVC Fig. 3 .", [["UVC", "CHEMICAL", 32, 35], ["prolonged exposure UVC Fig", "TREATMENT", 13, 39], ["UVC Fig", "OBSERVATION", 32, 39]]], ["Position of the robot in the room could damage eyes so always run the robot in an empty room.", [["eyes", "ANATOMY", 47, 51], ["eyes", "ORGAN", 47, 51]]], ["Should motion be detected during the pulsing of the light the gray cone will turn the device off you will use the device after you've finished cleaning a room but before the bed is made.", [["the device", "TREATMENT", 82, 92], ["the device", "TREATMENT", 110, 120]]], ["For most rooms treating the bathroom with the UVC light first will save time because it is possible to work in the room while it is treating the bathroom (Fig. 4) .Service Robots for DisinfectionLike common illnesses for which humans ingest antibiotics, each pathogen that causes the most common healthcare associated infections has a known dosage, specifically a UVC dosage, at which it is deactivated or terminated.", [["UVC", "CHEMICAL", 46, 49], ["infections", "DISEASE", 318, 328], ["UVC", "CHEMICAL", 364, 367], ["humans", "ORGANISM", 227, 233], ["humans", "SPECIES", 227, 233], ["humans", "SPECIES", 227, 233], ["the UVC light", "TREATMENT", 42, 55], ["DisinfectionLike common illnesses", "PROBLEM", 183, 216], ["humans ingest antibiotics", "TREATMENT", 227, 252], ["each pathogen", "PROBLEM", 254, 267], ["a UVC dosage", "TREATMENT", 362, 374], ["infections", "OBSERVATION", 318, 328]]], ["UVC disinfection dosage is a function of total intensity of UVC light and the length of exposure.", [["UVC", "CHEMICAL", 0, 3], ["UVC", "CHEMICAL", 60, 63], ["UVC disinfection", "TREATMENT", 0, 16], ["UVC light", "TREATMENT", 60, 69], ["disinfection", "OBSERVATION", 4, 16], ["total", "OBSERVATION_MODIFIER", 41, 46], ["intensity", "OBSERVATION_MODIFIER", 47, 56], ["UVC light", "OBSERVATION", 60, 69], ["length", "OBSERVATION_MODIFIER", 78, 84]]], ["Using higher intensity UVC light decreases the time needed to reach the appropriate dosage.", [["UVC", "CHEMICAL", 23, 26], ["higher intensity UVC light", "TREATMENT", 6, 32]]], ["Likewise, using lower intensity UV light lengthens the amount of time needed to reach the right UV dosage to kill dangerous pathogens [3] .Service Robots for DisinfectionWhat that means is that running a UV robot for less time than needed to achieve the germ-killing UV dosage enables HAI-causing pathogens to survive, creating the opportunity for patients to become seriously ill.", [["germ", "ANATOMY", 254, 258], ["patients", "ORGANISM", 348, 356], ["patients", "SPECIES", 348, 356], ["lower intensity UV light lengthens", "TREATMENT", 16, 50], ["dangerous pathogens", "PROBLEM", 114, 133], ["a UV robot", "TREATMENT", 202, 212], ["pathogens", "PROBLEM", 297, 306], ["seriously ill", "PROBLEM", 367, 380], ["right", "ANATOMY_MODIFIER", 90, 95]]], ["The best way to prevent under-dosing, is to use UV robots that automatically measure room conditions in real time to calculate the power and time needed to achieve the right dosage.Service Robots for DisinfectionWith germ-killing UV light robots, there's no guessing when disinfection is achieved.", [["UV robots", "TREATMENT", 48, 57], ["DisinfectionWith germ", "PROBLEM", 200, 221], ["killing UV light robots", "TREATMENT", 222, 245], ["disinfection", "PROBLEM", 272, 284], ["right", "ANATOMY_MODIFIER", 168, 173]]], ["This patent pending SmartDosage UV technology incorporates proprietary algorithms that automatically adjust UVC dosage and treatment time as the robot operates, ensuring effective, complete treatment irrespective of variables such as room size, layout, furnishings, and environmental characteristics.", [["UVC", "CHEMICAL", 108, 111], ["SmartDosage UV technology", "TREATMENT", 20, 45], ["proprietary algorithms", "TREATMENT", 59, 81], ["UVC dosage", "TREATMENT", 108, 118], ["treatment time", "TREATMENT", 123, 137], ["patent", "OBSERVATION", 5, 11], ["size", "OBSERVATION_MODIFIER", 239, 243]]], ["Figure 5 shows a robot which is used for disinfection of surgical theaters.", [["a robot", "TREATMENT", 15, 22], ["disinfection of surgical theaters", "TREATMENT", 41, 74], ["surgical theaters", "OBSERVATION", 57, 74]]], ["UVC robots provide hospitals, nursing homes and other critical care environments with the assurance that dangerous pathogens like Clostridium difficile (C. diff), Acinetobacter and M.R.S.A., to name a few, are attacked before the next patient occupies the room [7] .", [["Clostridium difficile", "DISEASE", 130, 151], ["Clostridium difficile", "ORGANISM", 130, 151], ["C. diff)", "ORGANISM", 153, 161], ["patient", "ORGANISM", 235, 242], ["Clostridium difficile", "SPECIES", 130, 151], ["patient", "SPECIES", 235, 242], ["Clostridium difficile", "SPECIES", 130, 151], ["C. diff)", "SPECIES", 153, 161], ["UVC robots", "TREATMENT", 0, 10], ["dangerous pathogens", "PROBLEM", 105, 124], ["Clostridium difficile", "PROBLEM", 130, 151], ["C. diff)", "PROBLEM", 153, 161], ["Acinetobacter", "PROBLEM", 163, 176]]], ["There is a large database of UVC effect on various organisms, from bacteria and viruses to fungi and spores.", [["spores", "ANATOMY", 101, 107], ["UVC", "CHEMICAL", 29, 32], ["UVC effect", "PROBLEM", 29, 39], ["various organisms", "PROBLEM", 43, 60], ["bacteria", "PROBLEM", 67, 75], ["viruses", "PROBLEM", 80, 87], ["fungi", "PROBLEM", 91, 96], ["spores", "PROBLEM", 101, 107], ["large", "OBSERVATION_MODIFIER", 11, 16], ["UVC effect", "OBSERVATION", 29, 39], ["various organisms", "OBSERVATION", 43, 60], ["bacteria", "OBSERVATION_MODIFIER", 67, 75], ["viruses", "OBSERVATION_MODIFIER", 80, 87], ["spores", "OBSERVATION_MODIFIER", 101, 107]]], ["Standard term used effective dose is defined as the UVC light required to inactivate 90% of a given population (also called log1).", [["the UVC light", "TREATMENT", 48, 61]]], ["Effective dose is defined as H UVC power \u00c2 time/irradiated area (Ws/m 2 ).", [["H UVC power", "TREATMENT", 29, 40], ["UVC", "ANATOMY", 31, 34]]], ["For example, E. coli requires a dose 30 Ws/m 2 while the standard fungi like Aspergillus niger requires a dose of 1320 Ws/m 2 .Service Robots for DisinfectionHeadgear-mers virus is one of RNA viruses and are categorized together should dose between 15-400 Ws/m 2 .", [["E. coli", "ORGANISM", 13, 20], ["Aspergillus niger", "ORGANISM", 77, 94], ["E. coli", "SPECIES", 13, 20], ["Aspergillus niger", "SPECIES", 77, 94], ["E. coli", "SPECIES", 13, 20], ["Aspergillus niger", "SPECIES", 77, 94], ["Headgear-mers virus", "SPECIES", 158, 177], ["E. coli", "PROBLEM", 13, 20], ["mers virus", "PROBLEM", 167, 177], ["RNA viruses", "PROBLEM", 188, 199], ["coli", "OBSERVATION", 16, 20]]], ["Examples of well-known RNA virus doses are 110 Ws poliovirus/m 2 , Newcastle disease 15 Ws/m 2 SARS 226 Ws/m 2 .", [["Newcastle disease", "DISEASE", 67, 84], ["SARS", "DISEASE", 95, 99], ["RNA virus doses", "TREATMENT", 23, 38], ["Newcastle disease", "PROBLEM", 67, 84]]], ["The assessment measured in the same region as high SARS can calculate real-time inactivity like to achieve 90% [3, 9] .Robot \"IRIS 3200 m\"IRIS 3200 m is the most powerful system for disinfecting UV light in the world.", [["SARS", "DISEASE", 51, 55], ["The assessment", "TEST", 0, 14], ["high SARS", "PROBLEM", 46, 55]]], ["His continuous UVC generate up to 20 times the UVC output tested xenon pulse system and three times the power of other constant light competitors.Robot \"IRIS 3200 m\"The patented PowerBoost technology enables iris 3200 m UVC robot to provide the whole room disinfection one position in far less time than any other unit on the market, but unlike most of the competition, attacking shadows where many of the harmful organisms are staying (in some cases many months).", [["UVC", "CHEMICAL", 15, 18], ["xenon", "CHEMICAL", 65, 70], ["xenon", "CHEMICAL", 65, 70], ["His continuous UVC", "TREATMENT", 0, 18], ["the UVC output", "TEST", 43, 57], ["xenon pulse system", "TREATMENT", 65, 83], ["UVC robot", "TREATMENT", 220, 229], ["the whole room disinfection", "TREATMENT", 241, 268], ["UVC", "OBSERVATION", 15, 18]]], ["Built Patent SmartDosage, together with the patented box Balance and PowerBoost technology allow iris 3200 m UV lighting system of disinfection for automatically measuring conditions the room environment, such as the size of the room, temperature and humidity in order to determine in real time the appropriate dose, time, number and power of the lamp is required for complete disinfection of all while providing maximum power permitted in the United States for the production of germicidal UVC energy.Robot \"IRIS 3200 m\"IRIS 3200 m is ideal for the hospital which require the maximum disinfection least amount of time.", [["UVC", "CHEMICAL", 491, 494], ["the patented box Balance", "TREATMENT", 40, 64], ["PowerBoost technology", "TREATMENT", 69, 90], ["disinfection", "TREATMENT", 131, 143], ["automatically measuring conditions", "PROBLEM", 148, 182], ["humidity", "TREATMENT", 251, 259], ["the lamp", "TEST", 343, 351], ["germicidal UVC energy", "TREATMENT", 480, 501], ["the maximum disinfection", "TREATMENT", 573, 597], ["Patent", "OBSERVATION", 6, 12]]], ["Managed by easy-to-use, wireless handheld Steri-Strip controller, iris 3200 m germ killing robot frees Environmental Services staff perform other tasks while the system is disinfected the whole room in one procedure.Robot \"IRIS 3200 m\"Benefits Iris 3200 m UV light disinfection system are:Robot \"IRIS 3200 m\"\u2022 Faster treatment room \u2022 Higher productivity \u2022 More effective treatments \u2022 Highly pathogenic kills prices \u2022 Whole-room treatments \u2022 One placement \u2022 One treatment High intensity ultraviolet light is produced by xenon flash lamps across the entire disinfecting spectrum known as UV-C.", [["xenon", "CHEMICAL", 519, 524], ["xenon", "CHEMICAL", 519, 524], ["wireless handheld Steri-Strip controller", "TREATMENT", 24, 64], ["one procedure", "TREATMENT", 202, 215], ["One placement", "TREATMENT", 441, 454], ["One treatment", "TREATMENT", 457, 470], ["High intensity ultraviolet light", "TREATMENT", 471, 503], ["xenon flash lamps", "TREATMENT", 519, 536], ["iris", "ANATOMY", 66, 70], ["High intensity", "OBSERVATION_MODIFIER", 471, 485]]], ["This UV-C energy passes through the cell walls of bacteria, viruses and bacterial spores.", [["cell walls", "ANATOMY", 36, 46], ["spores", "ANATOMY", 82, 88], ["cell walls", "CELLULAR_COMPONENT", 36, 46], ["This UV-C energy passes", "TREATMENT", 0, 23], ["bacteria", "PROBLEM", 50, 58], ["viruses", "PROBLEM", 60, 67], ["bacterial spores", "PROBLEM", 72, 88], ["cell", "ANATOMY", 36, 40], ["walls", "ANATOMY_MODIFIER", 41, 46], ["bacteria", "OBSERVATION", 50, 58], ["viruses", "OBSERVATION", 60, 67], ["bacterial spores", "OBSERVATION", 72, 88]]], ["The DNA, RNA and proteins inside the microorganism absorb this intense UV-C energy.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["The DNA, RNA and proteins inside the microorganism", "PROBLEM", 0, 50], ["C energy", "OBSERVATION_MODIFIER", 74, 82]]], ["Xenex Full Spectrum UV-C provides four mechanisms of damage against pathogens (Fig. 6) .Robot \"IRIS 3200 m\"Pathogens are vulnerable to UV-C light damage at different wavelengths depending on the organism.", [["UV-C", "CHEMICAL", 20, 24], ["Xenex", "TREATMENT", 0, 5], ["damage against pathogens", "PROBLEM", 53, 77], ["Pathogens", "PROBLEM", 107, 116], ["light damage at different wavelengths", "PROBLEM", 140, 177], ["the organism", "PROBLEM", 191, 203]]], ["Xenex's Pulsed Xenon lamps produce a flash of Full Spectrum germicidal light across the entire disinfecting spectrum (from 200 to 320 nm) delivered in millisecond pulses [10, 11] .Robot \"IRIS 3200 m\"The primary types of cellular damage caused by Pulsed Xenon UV are photohydration (pulling water molecules into the DNA that prevents transcription), photosplitting (breaking the backbone of the DNA), and photodimerization (improper fusing of DNA bases), all of which prevent cell replication.", [["cellular", "ANATOMY", 220, 228], ["cell", "ANATOMY", 475, 479], ["cellular damage", "DISEASE", 220, 235], ["Xenon UV", "CHEMICAL", 253, 261], ["cellular", "CELL", 220, 228], ["DNA", "CELLULAR_COMPONENT", 315, 318], ["DNA", "CELLULAR_COMPONENT", 394, 397], ["DNA", "CELLULAR_COMPONENT", 442, 445], ["cell", "CELL", 475, 479], ["Xenex's Pulsed Xenon lamps", "TREATMENT", 0, 26], ["Full Spectrum germicidal light", "TREATMENT", 46, 76], ["millisecond pulses", "TEST", 151, 169], ["cellular damage", "PROBLEM", 220, 235], ["Pulsed Xenon UV", "TREATMENT", 246, 261], ["photohydration", "TREATMENT", 266, 280], ["pulling water molecules", "TREATMENT", 282, 305], ["the DNA", "TREATMENT", 311, 318], ["photosplitting", "TREATMENT", 349, 363], ["photodimerization", "TREATMENT", 404, 421], ["cell replication", "TREATMENT", 475, 491], ["cellular damage", "OBSERVATION", 220, 235], ["cell replication", "OBSERVATION", 475, 491]]], ["Additionally, photo crosslinking causes cell wall damage and can cause cell lysis, an irreversible form of cell death.", [["cell wall", "ANATOMY", 40, 49], ["cell", "ANATOMY", 71, 75], ["cell", "ANATOMY", 107, 111], ["death", "DISEASE", 112, 117], ["cell wall", "TISSUE", 40, 49], ["cell", "CELL", 71, 75], ["cell", "CELL", 107, 111], ["photo crosslinking", "TREATMENT", 14, 32], ["cell wall damage", "PROBLEM", 40, 56], ["cell lysis", "PROBLEM", 71, 81], ["cell death", "PROBLEM", 107, 117], ["cell wall damage", "OBSERVATION", 40, 56], ["cell lysis", "OBSERVATION", 71, 81], ["irreversible", "OBSERVATION_MODIFIER", 86, 98], ["cell death", "OBSERVATION", 107, 117]]], ["Disinfecting across the entire spectrum helps prevent pathogens from repairing themselves [11] (Fig. 7) .", [["pathogens", "PROBLEM", 54, 63]]], ["There are cheaper ways to generate disinfecting UV light.", [["disinfecting UV light", "TREATMENT", 35, 56]]], ["For example, mercury lamps have been used to disinfect surfaces and liquids for decades, and the bulbs are only about $100.", [["bulbs", "ANATOMY", 97, 102], ["mercury", "CHEMICAL", 13, 20], ["mercury", "CHEMICAL", 13, 20], ["mercury", "SIMPLE_CHEMICAL", 13, 20], ["bulbs", "ORGAN", 97, 102], ["mercury lamps", "TREATMENT", 13, 26], ["bulbs", "ANATOMY", 97, 102]]], ["However, they are 25,000 times less intense than a Xenon bulb and the disinfection process can take hours, making them impractical for hospital use.", [["Xenon bulb", "MULTI-TISSUE_STRUCTURE", 51, 61], ["a Xenon bulb", "TREATMENT", 49, 61], ["the disinfection process", "TREATMENT", 66, 90]]], ["LEDs could also provide cheaper UV light, but they are also far less intense than Xenon bulbs, according to Hart [5, 11] (Fig. 8) .Robot \"IRIS 3200 m\"Advantage of UV light is that it kills germs without the use of chemicals.", [["germs", "ANATOMY", 189, 194], ["germs", "ORGAN", 189, 194], ["UV light", "TREATMENT", 163, 171]]], ["But surfaces need to be cleaned of fluids and dust first.", [["fluids", "TREATMENT", 35, 41]]], ["UV light adds a final layer of protection.", [["UV light", "TREATMENT", 0, 8], ["a final layer of protection", "TREATMENT", 14, 41], ["layer", "OBSERVATION_MODIFIER", 22, 27]]], ["When produced artificially here on Earth, UV-C rays can be blocked by a barrier as thin as a plastic bag.", [["UV-C rays", "TREATMENT", 42, 51], ["a plastic bag", "TREATMENT", 91, 104], ["plastic bag", "OBSERVATION", 93, 104]]], ["The robot comes with a motion sensor that turns itself off if it senses movement in the room while it is at work [3, 9] .ConclusionStudy showed that a \"no-touch\" semi-automated system, the UV light, was effective in substantially reducing the heterotrophic bacterial and MRSA burden on high-touch surfaces in rooms vacated by MRSA-positive patients.", [["MRSA", "CHEMICAL", 326, 330], ["patients", "ORGANISM", 340, 348], ["MRSA", "SPECIES", 271, 275], ["MRSA", "SPECIES", 326, 330], ["patients", "SPECIES", 340, 348], ["the heterotrophic bacterial and MRSA burden", "PROBLEM", 239, 282], ["MRSA", "PROBLEM", 326, 330], ["heterotrophic bacterial", "OBSERVATION", 243, 266], ["MRSA", "OBSERVATION", 271, 275], ["MRSA", "OBSERVATION", 326, 330]]], ["UVC disinfection may add to the armamentarium against HAI's without risking the adaptive genetic resistance incurred by pharmaceutical weapons.", [["UVC", "CHEMICAL", 0, 3], ["HAI", "DISEASE", 54, 57], ["UVC disinfection", "TREATMENT", 0, 16], ["HAI's", "PROBLEM", 54, 59], ["disinfection", "OBSERVATION", 4, 16], ["pharmaceutical weapons", "OBSERVATION", 120, 142]]], ["Implementation including training personnel to operate the device is minimal, and time spent cleaning was not increased.", [["training personnel", "TREATMENT", 25, 43], ["the device", "TREATMENT", 55, 65], ["minimal", "OBSERVATION_MODIFIER", 69, 76], ["increased", "OBSERVATION_MODIFIER", 110, 119]]], ["Because there were separate cycles for bathroom and living room, the surface reduction in aerobic colony counts may be better than with other UV systems; a head-to-head comparison of UV area disinfection devices may be warranted.", [["surface", "ANATOMY", 69, 76], ["colony", "ANATOMY", 98, 104], ["head", "ANATOMY", 156, 160], ["head", "ORGANISM_SUBDIVISION", 156, 160], ["the surface reduction", "TREATMENT", 65, 86], ["aerobic colony counts", "TEST", 90, 111], ["a head-to-head comparison", "TEST", 154, 179], ["UV area disinfection devices", "TREATMENT", 183, 211], ["aerobic colony", "OBSERVATION", 90, 104], ["head", "ANATOMY", 156, 160], ["head", "ANATOMY", 164, 168]]]], "PMC7320838": [["DiscussionDuring the outbreak of COVID-19, cancer patients are interrupted or delayed in review or treatment, which is not conducive to the patient's life and health.", [["cancer", "ANATOMY", 43, 49], ["cancer", "DISEASE", 43, 49], ["cancer", "CANCER", 43, 49], ["patients", "ORGANISM", 50, 58], ["patient", "ORGANISM", 140, 147], ["patients", "SPECIES", 50, 58], ["patient", "SPECIES", 140, 147], ["treatment", "TREATMENT", 99, 108]]], ["This commentary provides suggestions to ensure breast cancer patients\u2019 safety and treatment, and avoid cross-infection of COVID-19.DiscussionWe also recommend that staff preparedness should not be ignored, such as providing clinic staff with necessary training about SARS-CoV-2 testing and use of standard precautions and personal protective equipment, which are also important measures to prevent SARS-CoV-2 infection according to American Society of Clinical Oncology (ASCO) guidance [3].", [["breast cancer", "ANATOMY", 47, 60], ["breast cancer", "DISEASE", 47, 60], ["SARS", "DISEASE", 267, 271], ["SARS-CoV-2 infection", "DISEASE", 398, 418], ["COVID-19", "CHEMICAL", 122, 130], ["breast cancer", "CANCER", 47, 60], ["patients", "ORGANISM", 61, 69], ["CoV-2", "ORGANISM", 403, 408], ["patients", "SPECIES", 61, 69], ["SARS-CoV-2", "SPECIES", 398, 408], ["breast cancer", "PROBLEM", 47, 60], ["treatment", "TREATMENT", 82, 91], ["COVID", "TEST", 122, 127], ["CoV-2 testing", "TEST", 272, 285], ["standard precautions", "TREATMENT", 297, 317], ["personal protective equipment", "TREATMENT", 322, 351], ["SARS", "PROBLEM", 398, 402], ["CoV-2 infection", "PROBLEM", 403, 418], ["breast", "ANATOMY", 47, 53], ["cancer", "OBSERVATION", 54, 60]]], ["Nowadays, as more and more asymptomatic carriers are diagnosed [4], we strongly recommend that SARS-CoV-2 testing and lung CT be listed as routine inspection items for every patient.", [["lung", "ANATOMY", 118, 122], ["lung", "ORGAN", 118, 122], ["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["SARS-CoV-2 testing", "TEST", 95, 113], ["lung CT", "TEST", 118, 125], ["lung", "ANATOMY", 118, 122]]], ["After the outbreak of COVID-19 in Wuhan, China, medical teams from other provinces came to Wuhan to participate in the rescue.", [["COVID-19", "CHEMICAL", 22, 30]]], ["When they finish the rescue and return to their work places, they will be quarantined for 14 days before starting normal work.DiscussionThis commentary focused on breast cancer patients and provided suggestions to avoid the spread of COVID-19.", [["breast cancer", "ANATOMY", 163, 176], ["breast cancer", "DISEASE", 163, 176], ["breast cancer", "CANCER", 163, 176], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["COVID", "TEST", 234, 239], ["breast", "ANATOMY", 163, 169], ["cancer", "OBSERVATION", 170, 176]]], ["Some of these suggestions are also suitable for cancer patients in other lesions.", [["cancer", "ANATOMY", 48, 54], ["lesions", "ANATOMY", 73, 80], ["cancer", "DISEASE", 48, 54], ["cancer", "CANCER", 48, 54], ["patients", "ORGANISM", 55, 63], ["lesions", "CANCER", 73, 80], ["patients", "SPECIES", 55, 63], ["cancer patients in other lesions", "PROBLEM", 48, 80], ["lesions", "OBSERVATION", 73, 80]]]], "PMC7471558": [["Novel coronavirus disease-2019 (COVID-19), was caused by severe acute respiratory syndrome coronavirus.1 The virus spreads across the world at an alarming rate leading to a pandemic and creating a severe burden to health care resources.", [["coronavirus disease", "DISEASE", 6, 25], ["acute respiratory syndrome coronavirus", "DISEASE", 64, 102], ["severe acute respiratory syndrome coronavirus", "SPECIES", 57, 102], ["Novel coronavirus disease", "PROBLEM", 0, 25], ["COVID", "TEST", 32, 37], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 57, 102], ["The virus spreads", "PROBLEM", 105, 122], ["a pandemic", "PROBLEM", 171, 181], ["a severe burden", "PROBLEM", 195, 210], ["coronavirus disease", "OBSERVATION", 6, 25], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["respiratory syndrome coronavirus", "OBSERVATION", 70, 102], ["virus", "OBSERVATION", 109, 114], ["severe", "OBSERVATION_MODIFIER", 197, 203]]], ["Inflammatory bowel diseases (IBD) are chronic conditions requiring lifelong treatment in the majority of patients with a high risk for surgery.2,3 Given the severity of the pandemic, it has been recommended by multiple associations and societies that elective surgery be postponed while urgent surgery should continue.4\u20136 The current survey study is aimed to evaluate changes in hospital admissions and surgeries during COVID-19 from the patient\u2019s perspective.", [["bowel", "ANATOMY", 13, 18], ["Inflammatory bowel diseases", "DISEASE", 0, 27], ["IBD", "DISEASE", 29, 32], ["4\u20136", "CHEMICAL", 318, 321], ["bowel", "ORGAN", 13, 18], ["patients", "ORGANISM", 105, 113], ["patient", "ORGANISM", 438, 445], ["patients", "SPECIES", 105, 113], ["patient", "SPECIES", 438, 445], ["Inflammatory bowel diseases", "PROBLEM", 0, 27], ["IBD)", "PROBLEM", 29, 33], ["chronic conditions", "PROBLEM", 38, 56], ["lifelong treatment", "TREATMENT", 67, 85], ["surgery", "TREATMENT", 135, 142], ["the pandemic", "PROBLEM", 169, 181], ["elective surgery", "TREATMENT", 251, 267], ["urgent surgery", "TREATMENT", 287, 301], ["The current survey study", "TEST", 322, 346], ["surgeries", "TREATMENT", 403, 412], ["COVID", "TEST", 420, 425], ["bowel", "ANATOMY", 13, 18], ["diseases", "OBSERVATION", 19, 27], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["surgery", "OBSERVATION", 135, 142], ["pandemic", "OBSERVATION", 173, 181]]]], "39cd0cd57b719987167c33fb3ae03f384bf76a22": [["Hubei province, China, which has caused severe illness and death.", [["illness", "DISEASE", 47, 54], ["death", "DISEASE", 59, 64], ["severe illness", "PROBLEM", 40, 54], ["death", "PROBLEM", 59, 64], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["illness", "OBSERVATION", 47, 54]]], ["2 With 11 million inhabitants, Wuhan is the largest transportation hub in central China, which is known as Chicago of China.", [["largest", "OBSERVATION_MODIFIER", 44, 51], ["central China", "ANATOMY", 74, 87]]], ["2, 3 China has taken a series of public health interventions to control the epidemic.", [["public health interventions", "TREATMENT", 33, 60]]], ["3 The outbreak of COVID-19 has become a public health event of global concern.", [["COVID-19", "CHEMICAL", 18, 26], ["COVID-19", "SPECIES", 18, 26], ["COVID", "TEST", 18, 23]]], ["4 Due to its relatively high infectivity, the rapid progression of the disease and the lack of clear and effective treatment, it has caused international anxiety.", [["anxiety", "DISEASE", 154, 161], ["its relatively high infectivity", "PROBLEM", 9, 40], ["the disease", "PROBLEM", 67, 78], ["effective treatment", "TREATMENT", 105, 124], ["international anxiety", "PROBLEM", 140, 161], ["relatively", "OBSERVATION_MODIFIER", 13, 23], ["high", "OBSERVATION_MODIFIER", 24, 28], ["infectivity", "OBSERVATION", 29, 40], ["rapid", "OBSERVATION_MODIFIER", 46, 51], ["progression", "OBSERVATION_MODIFIER", 52, 63], ["disease", "OBSERVATION", 71, 78]]], ["4, 5 In fact, it has also caused illness in a significant proportion of exposed medical personnel.", [["illness", "DISEASE", 33, 40], ["illness", "PROBLEM", 33, 40]]], ["6 Since identification of COVID-19 was confirmed in December 2019, the number of cases has shown an upward trend, and the epidemiological picture is changing every day.", [["COVID-19", "DNA", 26, 34], ["COVID", "TEST", 26, 31], ["an upward trend", "PROBLEM", 97, 112], ["upward", "OBSERVATION_MODIFIER", 100, 106], ["trend", "OBSERVATION_MODIFIER", 107, 112]]], ["With lack of any effective vaccine or drug currently available, scientists and doctors are conducting a series of clinical studies involving affected patients.", [["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["any effective vaccine", "TREATMENT", 13, 34], ["clinical studies", "TEST", 114, 130]]], ["7, 8 Although Chinese researchers are struggling to find effective treatments and preventive measures, and actively conduct clinical trials, one aspect of the clinical trials has been surprisingly overlooked.", [["effective treatments", "TREATMENT", 57, 77], ["preventive measures", "TREATMENT", 82, 101]]]], "03dbf1feb067f3dce6bf705a32e19416acce7b4f": [["Introductionbut also can be relevant to understand patterns in deaths, e.g. if sudden outbreaks collapse 105 the healthcare system. variables are expected to explain mainly COVID-19-related health outcomes (deaths), as 151 they are proxies for healthcare access and quality and also reflect other broader 152 inequalities in the population.", [["deaths", "DISEASE", 63, 69], ["deaths", "DISEASE", 207, 213], ["sudden outbreaks collapse", "PROBLEM", 79, 104]]], ["A dummy variable was constructed to capture whether 153 individuals report having at least one COVID-19-related health conditions, as reported by 154 the Centers for Disease Control and Prevention (CDC) and the information reported by 155 the Chilean Ministry of Health, (13, 57, 58).", [["A dummy variable", "PROBLEM", 0, 16], ["Disease Control", "TREATMENT", 166, 181]]], ["Given the 158 nature of the virus, access to water is expected to impact people's preventive behavior, 159 particularly when hand washing has been identified as a key prevention strategy for the redefine poverty to include anything and everything that contributes to poor health, we 174 will make little progress either in theory or practice.\" (66).", [["hand", "ANATOMY", 125, 129], ["people", "ORGANISM", 73, 79], ["hand", "ORGANISM_SUBDIVISION", 125, 129], ["people", "SPECIES", 73, 79], ["the virus", "PROBLEM", 24, 33], ["hand washing", "TREATMENT", 125, 137]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194951 doi: medRxiv preprint models including this index and others in which the different dimensions-income 176 poverty, overcrowding, education, health insurance coverage, and job status-are 177 considered independently.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["this index", "TEST", 378, 388], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["All these variables can explain infections and deaths by 178 capturing the household's structural inability to follow the preventive measures (hand-179 washing, use of face masks, physical distancing, and quarantines) and seek healthcare 180 (e.g. health literacy) (70-75).", [["infections", "DISEASE", 32, 42], ["deaths", "DISEASE", 47, 53], ["infections", "PROBLEM", 32, 42], ["face masks", "TREATMENT", 168, 178]]], ["Finally, the use of public transportation and the availability 181 of green spaces capture people's ability to stay at home and comply with social 182 distancing strategies.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["public transportation", "TREATMENT", 20, 41]]], ["These are expected to impact the infection rate but can also 183 influence COVID-19 deaths, since they also show difficulty to move within the city, a 184 factor that could be relevant in case of health emergencies (76,77) 185 Finally, maps and spatial information were obtained from the website of the Inter- 186 Ministerial Committee on Geographic Information (78).", [["infection", "DISEASE", 33, 42], ["deaths", "DISEASE", 84, 90], ["the infection rate", "PROBLEM", 29, 47], ["maps", "TEST", 236, 240], ["infection", "OBSERVATION", 33, 42]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 18, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["To acknowledge the temporal dynamics of the disease, the study uses a standardized 100-201 days period since the first case was reported in each municipality.", [["the disease", "PROBLEM", 40, 51], ["the study", "TEST", 53, 62], ["temporal", "OBSERVATION_MODIFIER", 19, 27], ["disease", "OBSERVATION", 44, 51]]], ["As for the role of space 202 and place in explaining COVID-19 cases and deaths, we used a spatial analysis approach 203 to look at the data.204To identify the determinants of infection and mortality due to COVID-19 in the 205 Metropolitan Region in Chile, we carried out multivariable regressions to explain the set 206 of dependent variables, using the three groups of explanatory variables described above.", [["deaths", "DISEASE", 72, 78], ["infection", "DISEASE", 175, 184], ["a spatial analysis approach", "TEST", 88, 115], ["infection", "PROBLEM", 175, 184], ["COVID", "TEST", 206, 211], ["multivariable regressions", "PROBLEM", 271, 296], ["dependent variables", "PROBLEM", 323, 342], ["infection", "OBSERVATION", 175, 184]]], ["In this case, we used a 215 first-order queen contiguity matrix, i.e. we defined as neighbors all municipalities that 216 share a border.", [["a 215 first-order queen contiguity matrix", "TREATMENT", 22, 63]]], ["Given the nature of the data-the existence of clusters in different areas of 217 the region and the high heterogeneity in the size of the municipalities-a distance-based 218 approach was discarded (79) .219To understand the impact of different variables in the incidence and mortality due to CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint219The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194951 doi: medRxiv preprint regression's residuals.", [["CC", "CHEMICAL", 292, 294], ["the data", "TEST", 20, 28], ["CC", "TEST", 292, 294], ["medRxiv", "TREATMENT", 627, 634], ["clusters", "OBSERVATION_MODIFIER", 46, 54], ["different", "OBSERVATION_MODIFIER", 58, 67], ["areas", "OBSERVATION_MODIFIER", 68, 73], ["high", "OBSERVATION_MODIFIER", 100, 104], ["heterogeneity", "OBSERVATION_MODIFIER", 105, 118], ["size", "OBSERVATION_MODIFIER", 126, 130], ["med", "ANATOMY", 397, 400]]], ["This test shows whether the residuals are randomly distributed.", [["This test", "TEST", 0, 9], ["the residuals", "PROBLEM", 24, 37], ["residuals", "OBSERVATION", 28, 37]]], ["If 226 the null hypothesis is rejected, the OLS analysis needs to be adjusted to consider the 227 spatial effects.", [["the null hypothesis", "PROBLEM", 7, 26], ["the OLS analysis", "TEST", 40, 56]]], ["There are two main strategies to estimate spatial autoregressive models: 228 spatial lag and spatial error.", [["spatial lag", "PROBLEM", 77, 88], ["main", "OBSERVATION_MODIFIER", 14, 18], ["spatial error", "OBSERVATION", 93, 106]]], ["The spatial lag model (also known as contagion model) 229 incorporates space as a right hand-side variable, estimating a coefficient for the spatial 230 effect; the error model does not incorporate spatial as a covariate, but includes it in the 231 structure of the residuals (81).", [["right hand", "ANATOMY", 82, 92], ["The spatial lag model", "TEST", 0, 21], ["the residuals", "TEST", 262, 275], ["right", "ANATOMY_MODIFIER", 82, 87]]], ["Conceptually, spatial lag models seem more appropriate to 232 adjust for spatial autocorrelation in the case of infections, since it is expected that the 233 number of COVID-19 cases in one municipality affects the cases in the neighboring 234 areas, the contagion effects.", [["infections", "DISEASE", 112, 122], ["spatial lag models", "TEST", 14, 32], ["infections", "PROBLEM", 112, 122], ["COVID", "TEST", 168, 173], ["infections", "OBSERVATION", 112, 122]]], ["However, this is not necessarily true for mortality, 235 particularly once controlling for the case incidence rate.", [["not necessarily", "UNCERTAINTY", 17, 32]]], ["In this case, a spatial error model 236 appears more suitable, since unobserved spatial effects are expected to drive the spatial 237 autocorrelation in the residuals.", [["a spatial error model", "TEST", 14, 35], ["more suitable", "OBSERVATION_MODIFIER", 48, 61]]], ["Consequently, spatially correlated regressions of cases 238 are adjusted using a spatial lag model, and an error model is utilized for the death 239 regressions.240Incidence and mortality data were collected and calculated using Microsoft Excel.241Descriptive statistics and multivariable regressions were estimated using STATA, and 242 spatial analysis and visualizations were conducted in GeoDa.", [["death", "DISEASE", 139, 144], ["a spatial lag model", "TEST", 79, 98], ["an error model", "TEST", 104, 118], ["the death", "PROBLEM", 135, 144], ["mortality data", "TEST", 178, 192], ["multivariable regressions", "TEST", 275, 300], ["STATA", "TEST", 322, 327], ["spatial analysis", "TEST", 337, 353], ["visualizations", "TEST", 358, 372]]], ["First, it is observed the large 246 heterogeneity in most variables between municipalities, both in the dependent and 247 independent variables.", [["large", "OBSERVATION_MODIFIER", 26, 31], ["246", "OBSERVATION_MODIFIER", 32, 35], ["heterogeneity", "OBSERVATION", 36, 49], ["most variables", "OBSERVATION_MODIFIER", 53, 67]]], ["As stated before, this reflects the different realities within the MR, 248 as well as the differences in terms of COVID-19 outcomes.", [["MR", "PROTEIN", 67, 69], ["the MR", "TEST", 63, 69], ["COVID", "TEST", 114, 119]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint245The copyright holder for this this version posted September 18, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["To identify how different variables relate to COVID-19 infections and deaths, several 278 multivariable regressions were estimated.", [["infections", "DISEASE", 55, 65], ["deaths", "DISEASE", 70, 76], ["COVID-19 infections", "PROBLEM", 46, 65]]], ["Table 3 presents the results for the infection-279 related dependent variables.", [["infection", "DISEASE", 37, 46], ["the infection", "PROBLEM", 33, 46], ["dependent variables", "PROBLEM", 59, 78], ["infection", "OBSERVATION", 37, 46]]], ["As shown in Table 1 , each variable has three different ways 280 to be measured: cumulative incidence rate (columns 1 and 2), peak of cases (columns 3 281 and 4), and days to the peak (columns 5 and 6).", [["cumulative incidence rate", "TEST", 81, 106], ["columns", "TEST", 108, 115], ["columns", "TEST", 141, 148], ["columns", "TEST", 185, 192]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint245The copyright holder for this this version posted September 18, 2020.287.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["In this case, four 307 different models are estimated for each one of the independent variables, cumulative 308 mortality rate (columns 1 to 4), peak of deaths (columns 5 to 8), and days to the peak of 309 deaths (columns 9 to 12).", [["deaths", "DISEASE", 153, 159], ["deaths", "DISEASE", 206, 212], ["mortality rate", "TEST", 112, 126], ["columns", "TEST", 128, 135], ["columns", "TEST", 161, 168], ["columns", "TEST", 214, 221]]], ["As before, each model is estimated using either the 310 multidimensional poverty index or a set of socioeconomic factors; additionally models 311 .", [["socioeconomic factors", "PROTEIN", 99, 120]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint287The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194951 doi: medRxiv preprint are estimated including and excluding the cumulative incidence rate of cases as 312 explanatory variable (even and odd columns, respectively). .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 335, 342], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint287The copyright holder for this this version posted September 18, 2020.317The first result is that the determinants of infections and deaths are not the same.318However, as expected, some variables seem to explain variation in both types of explaining cumulative rates than peaks and days to the peak, and the overall fit (R 2 ) is 328 larger than for the infection regressions in Table 3 .", [["CC", "CHEMICAL", 0, 2], ["infections", "DISEASE", 331, 341], ["deaths", "DISEASE", 346, 352], ["infection", "DISEASE", 568, 577], ["ND", "PROBLEM", 9, 11], ["infections", "PROBLEM", 331, 341], ["deaths", "PROBLEM", 346, 352], ["the infection regressions", "PROBLEM", 564, 589], ["med", "ANATOMY", 105, 108], ["infections", "OBSERVATION", 331, 341], ["larger", "OBSERVATION_MODIFIER", 548, 554], ["infection", "OBSERVATION", 568, 577]]], ["As before, using Poisson regressions 329 for days to the peak does not change the main results.330.", [["Poisson regressions", "TEST", 17, 36]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Unlike the infection regressions, in this case, the hypothesis of a random spatial 331 distribution of the residuals is rejected in 8 out of 12 cases, highlighting the need to use 332 spatial regression models to take into account the presence of spatial autocorrelation.333Based on the results from Tables 3 and 4, a simplified set of regressions is estimated.", [["infection", "DISEASE", 11, 20], ["the infection regressions", "PROBLEM", 7, 32], ["the residuals", "PROBLEM", 103, 116], ["332 spatial regression models", "TREATMENT", 180, 209], ["infection", "OBSERVATION", 11, 20], ["residuals", "OBSERVATION", 107, 116]]], ["A 334 potential problem with inference, in this case, is related to the degrees of freedom due to 335 a large number of explanatory variables and the relatively small sample (n=52).", [["334 potential", "OBSERVATION_MODIFIER", 2, 15], ["large", "OBSERVATION_MODIFIER", 104, 109], ["number", "OBSERVATION_MODIFIER", 110, 116], ["small", "OBSERVATION_MODIFIER", 161, 166]]], ["Table 5 336 shows these reduced models, based on the previous results (infection and deaths OLS First, adding a spatial dimension removes the spatial correlation in the residuals in six 357 cases where OLS residuals show spatial autocorrelation: days to peak of cases (column 358 1), peak of deaths (columns 2 to 5), and days to peaks of deaths (columns 6 to 10).359However, overall the results improve, reflecting the addition of a previously omitted 360 significant variable.", [["infection", "DISEASE", 71, 80], ["deaths", "DISEASE", 85, 91], ["deaths", "DISEASE", 292, 298], ["deaths", "DISEASE", 338, 344], ["these reduced models", "TREATMENT", 18, 38], ["OLS residuals", "TEST", 202, 215], ["columns", "TEST", 300, 307], ["columns", "TEST", 346, 353]]], ["Not only overall fit increases (R 2 ) but also results in terms of 361 .", [["overall", "OBSERVATION_MODIFIER", 9, 16], ["fit", "OBSERVATION_MODIFIER", 17, 20], ["increases", "OBSERVATION_MODIFIER", 21, 30]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194951 doi: medRxiv preprint individual coefficients become more consistent.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["As Table 6 shows, the percentage of 362 children and the rurality reduces the magnitude in the peak of deaths but makes it quickly 363 (reduce the days to the peak).", [["deaths", "DISEASE", 103, 109], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48]]], ["The opposite occurs for multidimensional poverty, again, a 364 risk factor to explain the level and velocity of deaths.", [["deaths", "DISEASE", 112, 118], ["a 364 risk factor", "PROBLEM", 57, 74]]], ["The speeding effect is also 365 observed for the percentage of people 65+, migrants, overcrowding, and distance to 366 health centers, while the years of education increase the number of days to reach the 367 peak.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69]]], ["As before, population density shows positive and significant coefficients for the 368 peak of deaths regressions. can be assumed in the short-term as \"explanatory\" but be used for long-term planning; on 400 the other hand, the second group of indicators are \"policy tools\" and can be used as 401 control knobs to short-term responses to the pandemic.402The article has some limitations that need to be taken into account when interpreting the 403 results.", [["deaths", "DISEASE", 94, 100], ["population density", "TEST", 11, 29], ["deaths regressions", "PROBLEM", 94, 112], ["long-term planning", "TREATMENT", 180, 198], ["density", "OBSERVATION", 22, 29], ["positive", "OBSERVATION_MODIFIER", 36, 44], ["significant", "OBSERVATION_MODIFIER", 49, 60]]], ["Second, as discussed above, most variables reflect structural factors-such as 410 demographic and socioeconomic features-that are not expected to change significantly 411 .", [["structural factors", "PROBLEM", 51, 69], ["socioeconomic features", "TEST", 98, 120]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint402The copyright holder for this this version posted September 18, 2020. . in a three-year period.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["This is also expected for \"policy tools\" variables (such as the 412 patterns of use of public transportation) in absence of a policy shock.", [["shock", "DISEASE", 133, 138], ["public transportation", "TREATMENT", 87, 108], ["a policy shock", "TREATMENT", 124, 138]]], ["In this analysis, the issue was 415 confronted by using several perspectives (infections and deaths, and levels and change).422The Metropolitan Region is a good case for spatial analysis but other geographical areas 423 could also be of interest to understand the COVID-19 dynamics and policy responses 424 (e.g. for establishing regional or international sanitary customs).", [["infections", "DISEASE", 78, 88], ["deaths", "DISEASE", 93, 99], ["this analysis", "TEST", 3, 16], ["infections", "PROBLEM", 78, 88], ["spatial analysis", "TEST", 170, 186], ["the COVID", "TEST", 260, 269]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint422The copyright holder for this this version posted September 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 322, 325]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint422The copyright holder for this this version posted September 18, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint422The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.15.20194951 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 335, 342], ["med", "ANATOMY", 105, 108]]]], "587d43b560a43045fc239bf7a3e125427f7f83f5": [["the Middle East which have risen with fossil fuel in the last one hundred years will be adversely hit in the transition to a greener world.", [["Middle", "ANATOMY_MODIFIER", 4, 10]]]], "6aa1dd578203fb22f94b4e0cdd5976dd3091b43d": [["IntroductionMaintaining hand hygiene is crucial for preventing the spread of infectious diseases, and it can help reduce mortality, morbidity and healthcare costs [1] .", [["hand", "ANATOMY", 24, 28], ["infectious diseases", "DISEASE", 77, 96], ["hand", "ORGANISM_SUBDIVISION", 24, 28], ["infectious diseases", "PROBLEM", 77, 96]]], ["The rise of the COVID-19 pandemic has shown how critical it is to wash hands frequently and properly to reduce the transmission of lethal viruses and germs.", [["germs", "ORGAN", 150, 155], ["the COVID", "TEST", 12, 21], ["lethal viruses and germs", "PROBLEM", 131, 155], ["rise", "OBSERVATION_MODIFIER", 4, 8]]], ["The pandemic has put the entire human race in an unprecedented crisis and cost many lives [2] .", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["unprecedented", "OBSERVATION_MODIFIER", 49, 62], ["crisis", "OBSERVATION", 63, 69]]], ["Since no vaccine has been invented yet, experts have identified frequent handwashing and social distancing as the two most effective ways to reduce the spread of the virus.", [["vaccine", "TREATMENT", 9, 16], ["the virus", "PROBLEM", 162, 171]]], ["A recent study shows that a country's handwashing culture is a \"very good\" predictor of the magnitude of its spread of COVID-19 [3] .", [["COVID-19", "CHEMICAL", 119, 127], ["A recent study", "TEST", 0, 14], ["a country's handwashing culture", "TEST", 26, 57], ["COVID", "TEST", 119, 124]]], ["According to guidelines by the World Health Organization (WHO) [4] , proper handwashing consists of several steps, which ensures that every area of the hands is properly disinfected.", [["hands", "ORGANISM_SUBDIVISION", 152, 157], ["hands", "ANATOMY", 152, 157], ["disinfected", "OBSERVATION", 170, 181]]], ["However, the average persons as well as the healthcare workers are often ignorant about proper arXiv:2009.10317v1 [cs.HC] 22 Sep 2020IntroductionPeople often forget to wash hands when necessary.", [["persons", "ORGANISM", 21, 28], ["persons", "SPECIES", 21, 28], ["People", "SPECIES", 145, 151]]], ["For example, it is very important to wash hands after returning to home, particularly in the context of infectious disease like COVID-19 [19] .", [["infectious disease", "DISEASE", 104, 122], ["infectious disease", "PROBLEM", 104, 122], ["infectious", "OBSERVATION", 104, 114]]], ["We need a comprehensive system that guarantees high accuracy of handwashing quality assessment, runs efficiently on a smartwatch to facilitate real-time feedback, and reminds the user to wash hands in different contexts.", [["hands", "ORGANISM_SUBDIVISION", 192, 197], ["handwashing quality assessment", "TEST", 64, 94]]], ["In addition to that, the system has to interact with the user in a touch-free manner in order to avoid further contamination.", [["a touch-free manner", "TREATMENT", 65, 84], ["further contamination", "PROBLEM", 103, 124]]], ["However, there exist several challenges towards developing such a system.", [["several", "OBSERVATION_MODIFIER", 21, 28]]], ["First, a proper handwashing involves a set of steps [4] where the same step can be performed differently by different people and even differently by the same person at different times.", [["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124], ["person", "SPECIES", 158, 164]]], ["The diversity in the gestures for same step as well as confounding gestures in different steps make it difficult to identify which steps a user performs or misses in a handwashing event.", [["diversity", "OBSERVATION_MODIFIER", 4, 13]]], ["Though this problem can be alleviated by using sensor data from both hands, wearing smartwatches on both wrists is neither convenient nor practical in free-living context.", [["wrists", "ANATOMY", 105, 111], ["wrists", "ORGANISM_SUBDIVISION", 105, 111], ["sensor data", "TEST", 47, 58], ["hands", "ANATOMY", 69, 74]]], ["It is challenging to detect the steps of proper handwashing, particularly using a single wrist device.IntroductionSecond, resources like processing capacity and battery life available in smartwatches are very low.", [["wrist", "ORGANISM_SUBDIVISION", 89, 94], ["a single wrist device", "TREATMENT", 80, 101], ["battery life", "TREATMENT", 161, 173]]], ["High accuracy solutions like neural network based models usually require a significant amount of resources.", [["neural network", "ANATOMY", 29, 43], ["neural network", "MULTI-TISSUE_STRUCTURE", 29, 43], ["High accuracy solutions", "PROBLEM", 0, 23], ["neural network", "OBSERVATION", 29, 43]]], ["It is challenging to run such models on the smartwatches with low latency in order to provide real-time feedback.IntroductionThird, different smartwatches have different amounts of resources as well as different numbers of other applications that need to share the resources.", [["low latency", "PROBLEM", 62, 73], ["other applications", "TREATMENT", 223, 241]]], ["In contrast to the solutions that require a fixed amount of resources, a solution that can trade-off between accuracy and resource requirements is more desirable because such an adaptive solution can provide room for other applications when needed as well as they can be used on devices with a wide range of resources.IntroductionFourth, a touch-free interaction between the watch and the user is needed to avoid further contamination, particularly in the context of infectious diseases.", [["infectious diseases", "DISEASE", 467, 486], ["a fixed amount of resources", "TREATMENT", 42, 69], ["a solution", "TREATMENT", 71, 81], ["an adaptive solution", "TREATMENT", 175, 195], ["further contamination", "PROBLEM", 413, 434], ["infectious diseases", "PROBLEM", 467, 486], ["infectious", "OBSERVATION", 467, 477]]], ["The tiny display of a smartwatch is also not suitable in providing detailed assessment results to the users.IntroductionIn this paper, we address each of the aforementioned challenges in a smartwatch based handwashing quality assessment system.", [["detailed assessment", "TEST", 67, 86], ["tiny", "OBSERVATION_MODIFIER", 4, 8]]], ["The main contributions of this paper are:Introduction\u2022 Handwashing quality assessment system on a smartwatch with high accuracy: We present iWash, a comprehensive handwashing quality assessment and a real-time reminder system on a smartwatch.", [["a comprehensive handwashing quality assessment", "TEST", 147, 193], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["We employ a hybrid deep neural network (combination of Convolutional Neural Network (CNN) and Recurrent Neural Network (RNN)) based method to detect the handwashing quality in terms of the standard guidelines and achieve around 12% accuracy improvement over the state-of-the-art systems. \u2022 Efficient smartwatch based system for providing immediate feedback: For the first time in smartwatchbased handwashing quality assessment solutions, we employ model compression technique to optimize the system in terms of the smartwatch constraints to run the system faster and with lower battery usage in addition to guaranteeing high accuracy.", [["neural network", "MULTI-TISSUE_STRUCTURE", 24, 38], ["a hybrid deep neural network", "TREATMENT", 10, 38], ["Convolutional Neural Network (CNN)", "TREATMENT", 55, 89], ["Recurrent Neural Network (RNN)", "TREATMENT", 94, 124], ["model compression technique", "TREATMENT", 448, 475], ["deep", "ANATOMY_MODIFIER", 19, 23], ["neural network", "OBSERVATION", 24, 38]]], ["We further show that our system is able to trade-off between accuracy and the resource requirements, and thus offers an adaptive solution as per the device specification. \u2022 A context-aware reminder system: In the context of the infectious diseases, iWash provides routine reminders for washing hands and also in the situation when the user enters home. \u2022 Touch-free interaction: iWash interacts with the users in a touch-free way, a critical requirement for a handwashing system to avoid further contamination from touching the devices.", [["infectious diseases", "DISEASE", 228, 247], ["iWash", "CHEMICAL", 249, 254], ["an adaptive solution", "TREATMENT", 117, 137], ["the infectious diseases", "PROBLEM", 224, 247], ["washing hands", "TREATMENT", 286, 299], ["a handwashing system", "TREATMENT", 458, 478], ["further contamination", "PROBLEM", 488, 509], ["touching the devices", "TREATMENT", 515, 535], ["infectious", "OBSERVATION", 228, 238]]], ["It intelligently uses voice interaction to overcome the tiny display challenge of the smartwatch and provides useful feedback to the user. \u2022 Real-life data collection: As there is no widely used publicly available dataset for handwashing quality assessment, we collected handwashing data from 14 participants in real-life setting and conducted extensive evaluations to demonstrate the performance superiority of iWash compared to the state-of-the-art systems.IntroductionThe rest of the paper is organized as follows.", [["iWash", "CHEMICAL", 412, 417], ["participants", "SPECIES", 296, 308], ["voice interaction", "PROBLEM", 22, 39], ["handwashing quality assessment", "TEST", 226, 256], ["handwashing data", "TEST", 271, 287], ["extensive evaluations", "TEST", 344, 365], ["no", "UNCERTAINTY", 180, 182], ["widely", "OBSERVATION_MODIFIER", 183, 189]]], ["Section 3 provides the basic overview of iWash.", [["iWash", "CANCER", 41, 46]]], ["Section 4 describes the details of each system component of iWash.", [["iWash", "PROTEIN", 60, 65]]], ["Both procedure consists of several steps which ensures that every portion of the hand is properly disinfected.", [["hand", "ANATOMY", 81, 85], ["hand", "ORGANISM_SUBDIVISION", 81, 85], ["Both procedure", "TREATMENT", 0, 14], ["hand", "ANATOMY", 81, 85], ["disinfected", "OBSERVATION", 98, 109]]], ["While the soap or the alcohol applying step on the hands are different, we can see that the key steps for cleaning different portions of the hands (step 2 through until step 7) are the same.", [["alcohol", "CHEMICAL", 22, 29], ["alcohol", "CHEMICAL", 22, 29], ["alcohol", "SIMPLE_CHEMICAL", 22, 29], ["hands", "ORGANISM_SUBDIVISION", 51, 56], ["hands", "ANATOMY", 141, 146]]], ["So, to cover both of the approaches, the existing handwashing quality assessments systems have focused on whether the steps 2 through 7 were properly performed by the user [14] [16] .", [["the existing handwashing quality assessments systems", "TEST", 37, 89]]], ["Moreover, by carefully observing these steps, we can see that the steps 3, 5, 6, and 7 involves an action to be repeated by opposite hands.", [["hands", "ORGANISM_SUBDIVISION", 133, 138]]], ["For example, the step 3 suggests that one should put the right palm over left dorsum with interlaced fingers and vice versa.", [["right palm", "ANATOMY", 57, 67], ["left dorsum", "ANATOMY", 73, 84], ["fingers", "ANATOMY", 101, 108], ["palm", "ORGANISM_SUBDIVISION", 63, 67], ["dorsum", "ORGANISM_SUBDIVISION", 78, 84], ["fingers", "ORGANISM_SUBDIVISION", 101, 108], ["right", "ANATOMY_MODIFIER", 57, 62], ["palm", "ANATOMY_MODIFIER", 63, 67], ["left", "ANATOMY_MODIFIER", 73, 77], ["dorsum", "ANATOMY", 78, 84], ["interlaced fingers", "ANATOMY", 90, 108]]], ["It means the user should put the right palm over left dorsum with interlaced fingers and also put the left palm over right dorsum with interlaced fingers.", [["right palm", "ANATOMY", 33, 43], ["left dorsum", "ANATOMY", 49, 60], ["left palm", "ANATOMY", 102, 111], ["right dorsum", "ANATOMY", 117, 129], ["palm", "ORGANISM_SUBDIVISION", 39, 43], ["dorsum", "ORGANISM_SUBDIVISION", 54, 60], ["fingers", "ORGANISM_SUBDIVISION", 77, 84], ["palm", "ORGANISM_SUBDIVISION", 107, 111], ["dorsum", "ORGANISM_SUBDIVISION", 123, 129], ["fingers", "ORGANISM_SUBDIVISION", 146, 153], ["right", "ANATOMY_MODIFIER", 33, 38], ["palm", "ANATOMY_MODIFIER", 39, 43], ["left", "ANATOMY_MODIFIER", 49, 53], ["dorsum", "ANATOMY", 54, 60], ["interlaced fingers", "ANATOMY", 66, 84], ["left", "ANATOMY_MODIFIER", 102, 106], ["palm", "ANATOMY_MODIFIER", 107, 111], ["right", "ANATOMY_MODIFIER", 117, 122], ["dorsum", "ANATOMY", 123, 129], ["interlaced fingers", "ANATOMY", 135, 153]]], ["So, for the convenience of evaluation, we break such steps into two steps and assign number for all the individual steps.", [["evaluation", "TEST", 27, 37]]], ["The steps from the WHO handrubbing and handwashing guidelines and the corresponding step numbers in iWash are presented in Table 1 .What is a Quality Assessment System for HandwashingIn most of the previous works, the adherence to the WHO handrub and handwash guidelines were measured [14] [15]What is a Quality Assessment System for Handwashing[16] [17] to assess the quality of hand hygiene.", [["hand", "ANATOMY", 380, 384], ["hand", "ORGANISM_SUBDIVISION", 380, 384], ["handwashing guidelines", "TREATMENT", 39, 61], ["the WHO handrub and handwash guidelines", "TREATMENT", 231, 270]]], ["Additionally, in the context of infectious diseases, CDC(Centers for Disease Control and Prevention) recommends performing handwashing or handrubbing for a period of minimum 20 seconds [19] .", [["infectious diseases", "DISEASE", 32, 51], ["infectious diseases", "PROBLEM", 32, 51], ["Disease Control", "TREATMENT", 69, 84], ["infectious", "OBSERVATION", 32, 42]]], ["Moreover, for the sake of uniformity, we will use the term handwashing throughout the paper, which will cover both handwash and handrub approaches.What is a Quality Assessment System for HandwashingIn a smartwatch based handwashing quality assessment system, the readings of the sensing modalities embedded in the smartwatch are used to identify the individual handwashing steps.", [["the term handwashing", "TREATMENT", 50, 70], ["the sensing modalities", "TREATMENT", 275, 297]]], ["In particular, when the user performs the handwashing steps, it involves movements of the wrists, which is captured by the IMU (Inetial Motion Unit) sensors of the smartwatch.", [["wrists", "ANATOMY", 90, 96], ["wrists", "ORGANISM_SUBDIVISION", 90, 96], ["wrists", "ANATOMY", 90, 96]]], ["These sensors readings are used to identify the corresponding handwashing steps.System Overview of iWashIn this section we discuss the system overview of iWash.", [["iWash", "SIMPLE_CHEMICAL", 154, 159], ["These sensors readings", "TEST", 0, 22]]], ["The user wears a smartwatch where the iWash application is previously installed. iWash includes a voice interactive reminder system that is used to remind the user through the smartwatch. iWash identifies the situation when the user enters home from outside and immediately provides a reminder to the user to wash hands.", [["iWash", "CHEMICAL", 81, 86], ["iWash", "CHEMICAL", 188, 193], ["hands", "ORGANISM_SUBDIVISION", 314, 319], ["a smartwatch", "TREATMENT", 15, 27], ["the iWash application", "TREATMENT", 34, 55]]], ["Also, the user is periodically reminded to wash hands in order to maintain the hand hygiene throughout the day.", [["hand", "ANATOMY", 79, 83], ["hand", "ORGANISM_SUBDIVISION", 79, 83]]], ["When the user starts to wash hands, iWash collects the accelerometer, gyroscope, and magnetometer sensor readings of the smartwatch throughout the handwashing event.", [["gyroscope", "TEST", 70, 79], ["magnetometer sensor readings", "TEST", 85, 113]]], ["The start and the end of the event are marked with the help of the voice interaction with the user.", [["marked", "OBSERVATION_MODIFIER", 39, 45]]], ["To build the model, we first develop a model which identifies the handwashing steps with high accuracy, however the model requires heavy computation.", [["heavy", "OBSERVATION_MODIFIER", 131, 136]]], ["Then we employ a model compression technique to create an optimized version of the model for running on the low-resource smartwatch.", [["a model compression technique", "TREATMENT", 15, 44]]], ["While optimizing the model, we focus on minimizing the prediction latency to meet the requirements for providing immediate feedback as well as preserving the high accuracy to identify the handwashing steps. iWash then identifies the steps missed by the user for a proper handwashing, and immediately reports it back to the user through a voice feedback. iWash also reports to the user if he/she did not wash hands for a minimum duration of 20 seconds.", [["hands", "ORGANISM_SUBDIVISION", 408, 413]]], ["In this way, iWash assesses the quality of the handwashing performed by the user and provides immediate feedback to the user.System Design of iWashBased on discussion of the system overview in the previous section, the system design of iWash has the following five major components.", [["iWash", "CHEMICAL", 236, 241]]], ["We provide detailed description for each of the components as below:Features Extraction from Handwashing EventDuring a handwashing event, data are collected from the accelerometer, gyroscope and magnetometer sensors of the smartwatch.", [["gyroscope", "TEST", 181, 190]]], ["The sensor data are collected at 50Hz sampling rate.", [["The sensor data", "TEST", 0, 15], ["sampling rate", "TEST", 38, 51]]], ["Each of the sensors provides data signals along the x, y, and z axes.", [["data signals", "TEST", 29, 41]]], ["Some pre-processing is needed to remove the noisy artifacts from the signals.", [["the noisy artifacts", "PROBLEM", 40, 59]]], ["Specifically, we pass the raw signals through a FIR (Finite Impulse Response) filter to remove the high-frequency vibration noises [21] .", [["FIR", "DNA", 48, 51], ["a FIR (Finite Impulse Response) filter", "TREATMENT", 46, 84], ["the high-frequency vibration noises", "TREATMENT", 95, 130]]], ["These values are picked according to the state-of-the-art paper [14] which led to the best results for handwashing quality assessment in their work.", [["These values", "TEST", 0, 12], ["handwashing quality assessment", "TEST", 103, 133]]], ["Once the windows is generated, we extract several statistical features from each window, such as the mean, standard deviation, kurtosis and skew.", [["standard deviation, kurtosis and skew", "PROBLEM", 107, 144]]], ["Moreover, previous works have shown that the empirical cumulative distribution function representation (ECDF) of the sensor data is effective in preserving the statistical characteristics of the data [22] .", [["the sensor data", "TEST", 113, 128]]], ["Consequently, in addition to the mean, standard deviation, kurtosis and skew, we also compute the ECDF feature from the sensor data along the three axes.", [["standard deviation, kurtosis and skew", "PROBLEM", 39, 76], ["the sensor data", "TEST", 116, 131]]], ["To develop a model that identifies handwashing steps with high accuracy, we develop a hybrid deep neural network as shown in Figure 3 .", [["neural network", "ANATOMY", 98, 112], ["neural network", "MULTI-TISSUE_STRUCTURE", 98, 112], ["a hybrid deep neural network", "PROBLEM", 84, 112]]], ["The model is a parallel combination of CNN and RNN.", [["CNN", "GENE_OR_GENE_PRODUCT", 39, 42], ["CNN", "PROTEIN", 39, 42], ["RNN", "PROTEIN", 47, 50], ["CNN and RNN", "TREATMENT", 39, 50]]], ["CNN and RNN allow capturing the spatial and temporal correlation present in input sensor data, respectively.", [["CNN", "GENE_OR_GENE_PRODUCT", 0, 3], ["CNN", "PROTEIN", 0, 3], ["RNN", "DNA", 8, 11]]], ["As a result, the combination of these two networks facilitate the identification of handwashing steps with high accuracy.A Hybrid Deep Neural Network Architecture for iWashAfter the sensor data are windowed from the previous step, the windowed data are provided to the hybrid deep neural network.", [["neural network", "ANATOMY", 281, 295], ["neural network", "MULTI-TISSUE_STRUCTURE", 281, 295], ["Deep", "ANATOMY_MODIFIER", 130, 134], ["Neural Network", "OBSERVATION", 135, 149], ["deep", "ANATOMY_MODIFIER", 276, 280], ["neural network", "OBSERVATION", 281, 295]]], ["The inputs to the hybrid network are the statistical features for a window and the activation vector for the previous window data.", [["hybrid network", "MULTI-TISSUE_STRUCTURE", 18, 32], ["a window", "TREATMENT", 66, 74], ["the activation vector", "TREATMENT", 79, 100], ["the previous window data", "TEST", 105, 129]]], ["Activation vector for a window is the concatenation of the CNN and RNN outputs for the window data.", [["CNN", "GENE_OR_GENE_PRODUCT", 59, 62], ["CNN", "DNA", 59, 62], ["RNN", "DNA", 67, 70], ["Activation vector", "TREATMENT", 0, 17], ["the window data", "TEST", 83, 98]]], ["By considering the activation vector for the previous window data in addition to the statistical features of the current window data as input to the hybrid network, we allow the flow of information from the previous windows.", [["hybrid network", "MULTI-TISSUE_STRUCTURE", 149, 163], ["the activation vector", "TREATMENT", 15, 36]]], ["A complete handwashing event consists of a sequence of handwashing steps, so identification of a handwashing step is facilitated if the previous handwashing steps are identified and kept into consideration.", [["a handwashing step", "PROBLEM", 95, 113]]], ["In essence, such flow of information from the previous windows facilitates the accurate identification of the subsequent steps.A Hybrid Deep Neural Network Architecture for iWashCNN Architecture: The CNN consists of three convolutional layers.", [["layers", "TISSUE", 236, 242], ["CNN", "PROTEIN", 200, 203], ["Deep", "ANATOMY_MODIFIER", 136, 140], ["Neural Network", "OBSERVATION", 141, 155], ["convolutional layers", "OBSERVATION", 222, 242]]], ["The filter size of the three convolutional layers are 3, 5, and 7, respectively.", [["convolutional layers", "ANATOMY", 29, 49], ["filter", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 11, 15], ["three", "OBSERVATION_MODIFIER", 23, 28], ["convolutional", "OBSERVATION_MODIFIER", 29, 42], ["layers", "OBSERVATION_MODIFIER", 43, 49]]], ["The number of filters in the three convolutional layers are 128, 256, and 512, respectively.", [["number", "OBSERVATION_MODIFIER", 4, 10], ["filters", "OBSERVATION", 14, 21], ["three", "ANATOMY_MODIFIER", 29, 34], ["convolutional", "ANATOMY_MODIFIER", 35, 48], ["layers", "ANATOMY_MODIFIER", 49, 55]]], ["The values of the filter size and number of filters of a convolutional layer are chosen based on evaluation on a validation set.", [["the filter size", "TREATMENT", 14, 29], ["a convolutional layer", "TREATMENT", 55, 76], ["evaluation", "TEST", 97, 107], ["a validation set", "TEST", 111, 127], ["filter", "OBSERVATION_MODIFIER", 18, 24], ["size", "OBSERVATION_MODIFIER", 25, 29], ["number", "OBSERVATION_MODIFIER", 34, 40], ["filters", "OBSERVATION_MODIFIER", 44, 51], ["layer", "OBSERVATION_MODIFIER", 71, 76]]], ["The convolutional layers capture the correlation among data from multiple sensors across multiple axes (i.e., x, y, and z).", [["convolutional layers", "TISSUE", 4, 24], ["layers", "OBSERVATION_MODIFIER", 18, 24]]], ["The output of each convolutional layer passes through the Relu activation function [23] .", [["Relu", "PROTEIN", 58, 62], ["The output", "TEST", 0, 10], ["output", "OBSERVATION_MODIFIER", 4, 10], ["layer", "OBSERVATION_MODIFIER", 33, 38]]], ["The squeeze and excite block [24] after the convolutional layers help to capture contextual information present in input features.", [["the convolutional layers", "TREATMENT", 40, 64]]], ["Finally, the average pooling layer reduces the number of parameters and contributes in increasing accuracy by introducing transitional invariance in the output of convolutional layer [25] .A Hybrid Deep Neural Network Architecture for iWashRNN Architecture: We use a LSTM (Long Term Short Memory) network as the representative of RNN due to its higher performance over the other RNN variants [26] .", [["RNN", "PROTEIN", 330, 333], ["the average pooling layer", "PROBLEM", 9, 34], ["increasing accuracy", "PROBLEM", 87, 106], ["convolutional layer", "PROBLEM", 163, 182], ["a LSTM (Long Term Short Memory) network", "TREATMENT", 265, 304], ["layer", "OBSERVATION_MODIFIER", 29, 34], ["reduces", "OBSERVATION_MODIFIER", 35, 42], ["number", "OBSERVATION_MODIFIER", 47, 53], ["increasing", "OBSERVATION_MODIFIER", 87, 97]]], ["The LSTM network has 50 cells, which is chosen based on evaluation on a validation set.", [["cells", "ANATOMY", 24, 29], ["LSTM network", "MULTI-TISSUE_STRUCTURE", 4, 16], ["cells", "CELL", 24, 29], ["LSTM network", "DNA", 4, 16], ["evaluation", "TEST", 56, 66], ["50 cells", "OBSERVATION_MODIFIER", 21, 29]]], ["Before the LSTM network, the input feature are passed through a self attention layer [24] .", [["LSTM network", "MULTI-TISSUE_STRUCTURE", 11, 23], ["LSTM network", "DNA", 11, 23]]], ["Overall, the RNN architecture captures the temporal relationship present among input features.Concatenation of CNN and RNN Outputs:The outputs of the CNN and RNN are concatenated.", [["CNN", "GENE_OR_GENE_PRODUCT", 111, 114], ["CNN", "GENE_OR_GENE_PRODUCT", 150, 153], ["RNN", "CANCER", 158, 161], ["RNN", "DNA", 13, 16], ["CNN", "PROTEIN", 111, 114], ["RNN", "PROTEIN", 119, 122], ["CNN", "DNA", 150, 153], ["RNN", "DNA", 158, 161], ["the CNN", "TEST", 146, 153], ["temporal", "OBSERVATION_MODIFIER", 43, 51]]], ["As mentioned before, the concatenated vector (or activation vector) of the CNN and RNN outputs are incorporated with the input features of the next window.", [["CNN", "GENE_OR_GENE_PRODUCT", 75, 78], ["concatenated vector", "DNA", 25, 44], ["CNN", "DNA", 75, 78], ["RNN", "DNA", 83, 86], ["the CNN and RNN outputs", "TEST", 71, 94]]], ["The concatenated vector is also passed through a fully connected network that outputs the handwashing step for the current window.", [["The concatenated vector", "TREATMENT", 0, 23]]], ["The fully connected network has 3 layers, each with 250 hidden units.", [["network", "MULTI-TISSUE_STRUCTURE", 20, 27]]], ["Smartwatches are limited-resource in terms of computation and energy efficiency.", [["energy efficiency", "OBSERVATION", 62, 79]]], ["To run iWash efficiently on the smartwatch, we need to optimize the high accuracy model described in the previous section so that it runs with minimal prediction latency and battery resource.", [["minimal prediction latency", "PROBLEM", 143, 169]]], ["We also need to preserve the accuracy of the high accuracy model during this optimization.", [["this optimization", "TREATMENT", 72, 89]]], ["To overcome this challenge, we employ a model compression technique that compresses the high accuracy model.A Reinforcement Learning based Model Optimization for SmartwatchSpecifically, we adopt AMC [27] as this is a state-of-the-art work on model compression focusing on the optimization of both accuracy and prediction latency.", [["a model compression technique", "TREATMENT", 38, 67], ["model compression", "TREATMENT", 242, 259], ["compression", "OBSERVATION", 248, 259]]], ["As battery usage depends on the computation duration, optimizing for prediction latency also ensures optimization for battery usage.A Reinforcement Learning based Model Optimization for SmartwatchIn a deep learning model, the number of FLoating point OPerations (FLOPs) represents how many computations (multiplications and additions) are required for the model.", [["prediction latency", "TEST", 69, 87], ["SmartwatchIn a deep learning model", "TREATMENT", 186, 220], ["FLoating point OPerations (FLOPs)", "TREATMENT", 236, 269]]], ["Thus, the greater the number of FLOPs, the higher the prediction latency is.", [["FLOPs", "GENE_OR_GENE_PRODUCT", 32, 37], ["greater", "OBSERVATION_MODIFIER", 10, 17], ["number", "OBSERVATION_MODIFIER", 22, 28], ["higher", "OBSERVATION_MODIFIER", 43, 49]]], ["We need to set the maximum number of FLOPs allowed in the optimized model.", [["FLOPs", "TREATMENT", 37, 42]]], ["Specifically, we consider a hyper-parameter \u03b1 \u2208 (0, 1) that represents the fraction of FLOPs of the high accuracy model allowed in the optimized model.", [["FLOPs", "PROTEIN", 87, 92]]], ["Thus, if the number of FLOPs of the high accuracy model is N and we set \u03b1 = 0.5, then the maximum number of FLOPs allowed in the optimized model is 0.5 * N .A Reinforcement Learning based Model Optimization for SmartwatchWe leverage reinforcement learning to efficiently and automatically explore the large design space of deep neural network models with the goal of finding a model that is optimal in terms of both accuracy and prediction latency.", [["neural network", "ANATOMY", 328, 342], ["neural network", "MULTI-TISSUE_STRUCTURE", 328, 342], ["FLOPs", "PROTEIN", 108, 113], ["SmartwatchWe leverage reinforcement", "TREATMENT", 211, 246], ["large", "OBSERVATION_MODIFIER", 301, 306], ["deep", "ANATOMY_MODIFIER", 323, 327], ["neural network", "ANATOMY", 328, 342]]], ["Figure 4 provides an overview of the reinforcement learning based model optimization procedure.", [["the reinforcement learning", "TREATMENT", 33, 59], ["model optimization procedure", "TREATMENT", 66, 94]]], ["At each iteration of the reinforcement learning, we compress the high accuracy model in a layer-by-layer manner by following an actor-critic algorithm.", [["the reinforcement learning", "TREATMENT", 21, 47], ["an actor-critic algorithm", "TEST", 125, 150], ["high", "OBSERVATION_MODIFIER", 65, 69]]], ["For each layer, we generate an embedding of the layer.", [["layer", "OBSERVATION_MODIFIER", 9, 14], ["layer", "OBSERVATION_MODIFIER", 48, 53]]], ["The embedding depends on the structure of the layer, number of FLOPs of the layer, total number of FLOPs reduced in previous layers, and the number of remaining FLOPs in the subsequent layers.", [["FLOPs", "GENE_OR_GENE_PRODUCT", 161, 166], ["FLOPs", "PROTEIN", 63, 68], ["FLOPs", "PROTEIN", 99, 104], ["FLOPs", "PROTEIN", 161, 166], ["layer", "OBSERVATION_MODIFIER", 46, 51], ["number", "OBSERVATION_MODIFIER", 53, 59], ["layer", "OBSERVATION_MODIFIER", 76, 81], ["total", "OBSERVATION_MODIFIER", 83, 88], ["number", "OBSERVATION_MODIFIER", 89, 95], ["FLOPs", "OBSERVATION_MODIFIER", 99, 104], ["reduced", "OBSERVATION_MODIFIER", 105, 112], ["layers", "OBSERVATION_MODIFIER", 125, 131], ["number", "OBSERVATION_MODIFIER", 141, 147], ["remaining", "OBSERVATION_MODIFIER", 151, 160], ["FLOPs", "OBSERVATION", 161, 166], ["layers", "OBSERVATION_MODIFIER", 185, 191]]], ["The layer is compressed with the sparsity ratio.", [["layer", "OBSERVATION_MODIFIER", 4, 9], ["compressed", "OBSERVATION", 13, 23]]], ["The higher the sparsity ratio, the more the layer is compressed.", [["higher", "OBSERVATION_MODIFIER", 4, 10], ["sparsity", "OBSERVATION_MODIFIER", 15, 23], ["layer", "OBSERVATION_MODIFIER", 44, 49], ["compressed", "OBSERVATION", 53, 63]]], ["Then the next layer is processed in the similar manner.", [["layer", "OBSERVATION_MODIFIER", 14, 19]]], ["After all the layer are compressed, the critic network evaluates the resultant model in terms of accuracy and number of FLOPs.", [["layer", "OBSERVATION_MODIFIER", 14, 19], ["compressed", "OBSERVATION", 24, 34]]], ["During the evaluation, it is also checked whether the number of FLOPs is less than the maximum allowed.", [["FLOPs", "GENE_OR_GENE_PRODUCT", 64, 69], ["the evaluation", "TEST", 7, 21]]], ["Finally, the reinforcement learning agent learns the optimal sparsity ratio for each layer of the high accuracy model.", [["the reinforcement learning agent", "TREATMENT", 9, 41]]], ["Each layer is compressed based on the corresponding sparsity ratio to generate the final optimized model.A Reinforcement Learning based Model Optimization for SmartwatchSpecifically, at each iteration of the reinforcement learning, we try to minimize the following loss function:A Reinforcement Learning based Model Optimization for Smartwatchwhere,A Reinforcement Learning based Model Optimization for SmartwatchIn Equation (1), y and x represent the ground truth and input features, respectively. s denotes the sparsity ratio generated by actor network (O A , Equation (2)) given embedding of the model layers (E, Equation (2)).", [["the reinforcement learning", "TREATMENT", 204, 230], ["A Reinforcement", "TREATMENT", 349, 364], ["SmartwatchIn Equation", "TREATMENT", 403, 424], ["layer", "OBSERVATION_MODIFIER", 5, 10], ["compressed", "OBSERVATION", 14, 24]]], ["L denotes the mean squared loss between ground truth (y) and the output generated by critic network (O C ). #F LOP represents the number of FLOPs in the model after compressing all the layers according to the corresponding sparsity ratios.", [["F LOP", "PROTEIN", 109, 114], ["the mean squared loss", "PROBLEM", 10, 31], ["the output", "TEST", 61, 71], ["LOP", "PROBLEM", 111, 114], ["mean", "OBSERVATION_MODIFIER", 14, 18], ["squared", "OBSERVATION_MODIFIER", 19, 26], ["loss", "OBSERVATION_MODIFIER", 27, 31], ["ground truth", "OBSERVATION", 40, 52]]], ["Each of the actor and critic networks has two hidden layers, each layer has 300 units.A Reinforcement Learning based Model Optimization for SmartwatchOverall, in Equation (1), L is the multiplication of two terms.", [["layers", "TISSUE", 53, 59]]], ["The first term finds the loss between ground truth y and the output generated by critic network O C where the critic network considers the action (sparsity ratio for each layer, s) generated by the actor network.", [["O C", "CHEMICAL", 96, 99], ["O C", "PROTEIN", 96, 99], ["loss", "OBSERVATION_MODIFIER", 25, 29]]], ["The second term is the logarithm of the number of FLOPs in the model after compressing each layer according to the corresponding sparsity ratio.", [["FLOPs", "PROTEIN", 50, 55]]], ["Thus if we minimize Equation (1), we try to maximize accuracy and minimize number of FLOPs.", [["accuracy", "TEST", 53, 61], ["FLOPs", "TEST", 85, 90]]], ["We use Adam optimizer [28] to minimize Equation (1).", [["Adam optimizer", "TREATMENT", 7, 21]]], ["The optimal sparsity ratios ensure the optimal compressed model.A Reinforcement Learning based Model Optimization for SmartwatchAs mentioned before, choosing the value of \u03b1 is a design choice.", [["\u03b1", "PROTEIN", 171, 172]]], ["With the increase of the value of this hyper-parameter, the prediction latency increases but the accuracy also increases as the model is allowed to be more complex.", [["the prediction latency", "PROBLEM", 56, 78], ["the accuracy", "TEST", 93, 105], ["increase", "OBSERVATION_MODIFIER", 9, 17]]], ["Due to such trade-off between accuracy and number of FLOPs which is controllable by tuning the value of \u03b1, iWash has the capability of being device adaptive.", [["\u03b1", "PROTEIN", 104, 105], ["iWash", "PROTEIN", 107, 112], ["FLOPs", "TREATMENT", 53, 58]]], ["For low-resource devices, we can choose a lower value of \u03b1 resulting in reduced number of FLOPs.", [["\u03b1", "PROTEIN", 57, 58], ["low-resource devices", "TREATMENT", 4, 24], ["reduced", "OBSERVATION_MODIFIER", 72, 79], ["number", "OBSERVATION_MODIFIER", 80, 86]]], ["This ensures that the model will run efficiently on the device with a little sacrifice of accuracy.", [["the device", "TREATMENT", 52, 62]]], ["On the other hand, for the devices having high available resources, setting a higher value of \u03b1 will involve higher number of FLOPs and will result in high accuracy.", [["\u03b1", "PROTEIN", 94, 95], ["the devices", "TREATMENT", 23, 34]]], ["The details of this trade-off and device adaptivity are discussed in Section 5.5.4 and Figure 12 illustrates the trade-off.", [["this trade", "TREATMENT", 15, 25], ["device adaptivity", "TREATMENT", 34, 51]]], ["For our scenario, we consider \u03b1 = 0.5 as it provides a satisfactory trade-off between accuracy and the number of FLOPs.", [["accuracy", "TEST", 86, 94]]], ["Moreover, iWash calculates the duration of the handwashing event from the start and the end of the handwashing found from the voice interaction with the user.", [["iWash", "PROTEIN", 10, 15]]], ["However, if there are no missing steps and the duration is at least 20 seconds, a feedback message is generated mentioning that the user washed hands perfectly.", [["missing steps", "PROBLEM", 25, 38]]], ["If there are multiple feedback messages, the messages are combined into a single message at the end.", [["multiple", "OBSERVATION_MODIFIER", 13, 21], ["feedback messages", "OBSERVATION", 22, 39]]], ["The feedback is then provided to the user using voice at the end of the interaction with the user.Reminder and Interaction ModuleThis module of iWash is used to remind the user for washing hands in different situations and interacting with the user throughout the handwashing event.", [["washing hands", "TREATMENT", 181, 194]]], ["The flow of a reminder in iWash is demonstrated in Figure 5 .", [["a reminder in iWash", "TEST", 12, 31], ["flow", "OBSERVATION_MODIFIER", 4, 8]]], ["The proximity beacon is a small wireless sensor that can be attached to any object.", [["a small wireless sensor", "TREATMENT", 24, 47], ["small", "OBSERVATION_MODIFIER", 26, 31]]], ["It broadcasts tiny radio signals which can be sensed by a smartwatch.", [["tiny radio signals", "PROBLEM", 14, 32], ["tiny", "OBSERVATION_MODIFIER", 14, 18], ["radio signals", "OBSERVATION", 19, 32]]], ["Each sensed beacon signal on the smartwatch is associated with a Received Signal Strength (RSSI) value, which indicates how distant the beacon is from the smartwatch.", [["Each sensed beacon signal", "PROBLEM", 0, 25]]], ["The iWash application installed on the smartwatch runs in background which continuously receives signals from any surrounding beacon.", [["iWash", "CHEMICAL", 4, 9], ["The iWash application", "TREATMENT", 0, 21]]], ["We use a simple scheme for detecting the home entrance.", [["a simple scheme", "TREATMENT", 7, 22]]], ["If the average RSSI value received from a beacon within the last 15 seconds is greater than a threshold value (-60 decibels), and if the beacon identifier matches with that of the door beacon, iWash identifies the situation as the user is entering the home.", [["RSSI", "PROTEIN", 15, 19], ["the average RSSI value", "TEST", 3, 25]]], ["Moreover, on detecting the home entry of the user, iWash invokes the reminder system to remind him/her for washing hands.Providing Routine RemindersIn the context of the infectious disease, it is also important to wash hands frequently throughout the day [19] , whether the user is inside or outside the home.", [["infectious disease", "DISEASE", 170, 188], ["hands", "ORGANISM_SUBDIVISION", 115, 120], ["hands", "ORGANISM_SUBDIVISION", 219, 224], ["the infectious disease", "PROBLEM", 166, 188], ["infectious", "OBSERVATION", 170, 180]]], ["Moreover, smartwatches are very effective for notifying the user in all situation. iWash provides daily handwashing reminders to the user between 9 AM to 9 PM.", [["iWash", "CHEMICAL", 83, 88]]], ["In order to overcome this challenge, iWash uses voice input and output instead of any text for interaction.", [["this challenge", "TREATMENT", 21, 35], ["voice input", "TREATMENT", 48, 59]]], ["The voice interaction also ensures that the user is interacted in a touchless manner, which is critical to avoid further contamination of any virus or germ.", [["germ", "ANATOMY", 151, 155], ["germ", "TISSUE", 151, 155], ["any virus", "PROBLEM", 138, 147]]], ["The voice interaction also ensures that the user is interacted in a touch-free way, which is critical to avoid further contamination of any germs or virus.", [["any germs or virus", "PROBLEM", 136, 154]]], ["While providing the reminder, iWash provides a local notification with a haptic vibration to alert the user.", [["a haptic vibration", "TREATMENT", 71, 89]]], ["It then initiates the voice interaction with the user and asks him/her to wash hands.", [["hands", "ORGANISM_SUBDIVISION", 79, 84]]], ["When the user responds using any voice utterance, iWash takes the input via the microphone of the smartwatch, and converts the audio to text using a speech-to-text framework.", [["iWash", "DNA", 50, 55]]], ["When the user confirms starting the handwashing, iWash starts collecting data from the accelerometer, gyroscope, and magnetometer sensors of the smartwatch.", [["gyroscope", "TEST", 102, 111]]], ["When the user confirms being done with handwashing, it stops collecting data and begins the quality assessment with the collected data.", [["handwashing", "TREATMENT", 39, 50], ["the quality assessment", "TEST", 88, 110], ["the collected data", "TEST", 116, 134]]], ["An example of the interaction between iWash and the user is demonstrated in Figure 6 .Postponing a ReminderThe user may not be in a situation or may not be willing to wash hands immediately after being reminded.", [["hands", "ORGANISM_SUBDIVISION", 172, 177], ["iWash", "PROTEIN", 38, 43]]], ["This design choice ensures that the user is reminded at a time of his/her own preference for washing hands.EvaluationWe performed a thorough evaluation to demonstrate the performance superiority achieved by iWash compared to the state-of-the-art smartwatch-based handwashing quality assessment systems.", [["a thorough evaluation", "TEST", 130, 151]]], ["How much battery of the smartwatch is consumed by iWash compared to the state-of-the-art systems?Real-life Dataset CollectionWe collected real-life handwashing data from 14 participants.", [["iWash", "CHEMICAL", 50, 55], ["participants", "SPECIES", 173, 185]]], ["The age range of the participants was from 25 to 35 years.", [["participants", "ORGANISM", 21, 33], ["participants", "SPECIES", 21, 33]]], ["Among the 14 participants, 10 were male and 4 were female.", [["participants", "ORGANISM", 13, 25], ["participants", "SPECIES", 13, 25]]], ["The app collects readings from the accelerometer, gyroscope, and magnetometer sensors of the smartwatch with 50Hz sampling rate.", [["gyroscope", "TEST", 50, 59], ["50Hz sampling rate", "TEST", 109, 127]]], ["An instructional video on the WHO handwashing guidelines was shown to the participants so that they could learn the process.", [["participants", "SPECIES", 74, 86]]], ["After 3 practice sessions, we collected data of 19 handwashing sessions from each participant.", [["participant", "SPECIES", 82, 93]]], ["During each session, the participant wore the smartwatch on the right hand with the data collection app running on it and then performed a handwashing event.", [["right hand", "ANATOMY", 64, 74], ["participant", "SPECIES", 25, 36], ["right", "ANATOMY_MODIFIER", 64, 69]]], ["The participants were asked to wear the watch in their own ways as well as to perform the handwashing steps in their own ways.", [["participants", "SPECIES", 4, 16]]], ["All the sessions were video-taped for collecting the ground truth of the handwashing steps.", [["video-taped", "TREATMENT", 22, 33]]], ["The collected data were used for the training of iWash.Training of iWashWe trained the high accuracy model (Section 4.2) with the collected real-life dataset and then optimized the model for minimizing prediction latency while preserving accuracy (Section 4.3).", [["The collected data", "TEST", 0, 18], ["the training of iWash", "TREATMENT", 33, 54]]], ["The training was performed in a server that has a Intel processor with 10 cores, 256GB RAM, and 4 Nvidia RTX 2080 Ti GPUs.", [["Ti", "CHEMICAL", 114, 116], ["GB RAM", "TEST", 84, 90]]], ["We used Keras [32] to implement and optimize the model.Implementation of iWashThe implementation of iWash requires a smartwatch and a proximity Bluetooth beacon.", [["iWash", "CHEMICAL", 100, 105], ["Keras", "TREATMENT", 8, 13], ["a proximity Bluetooth beacon", "TREATMENT", 132, 160]]], ["In this work, we implemented iWash in real-life setting, where we used an Apple watch series 4 [33] and an Estimote BLE beacon [29] .", [["an Apple watch series", "TEST", 71, 92], ["an Estimote BLE beacon", "TEST", 104, 126]]], ["The iWash smartwatch application was developed on the watchOS platform and the trained optimized model (Section 5.2) was integrated with it.", [["The iWash smartwatch application", "TREATMENT", 0, 32]]], ["The iWash application was installed on the Apple watch where it was running on background.Implementation of iWashEstimote beacons are one of the most popular, low-energy, proximity bluetooth beacons.", [["iWashEstimote beacons", "PROBLEM", 108, 129], ["bluetooth beacons", "OBSERVATION", 181, 198]]], ["An estimote beacon was fitted at the door of the home and the user was wearing the Apple watch.", [["An estimote beacon", "PROBLEM", 0, 18]]], ["As described in Section 4.5, using the beacon and the smartwatch application, iWash reminds the user for handwashing and engages the user in a voice interaction (shown in Figure 7) .Implementation of iWashWe deployed iWash with the 14 participants for testing.", [["participants", "SPECIES", 235, 247], ["the beacon", "TREATMENT", 35, 45], ["the smartwatch application", "TREATMENT", 50, 76], ["testing", "TEST", 252, 259]]], ["During testing, each participant did 1 session wearing the smartwatch with the iWash application installed.", [["participant", "SPECIES", 21, 32], ["testing", "TEST", 7, 14], ["the smartwatch", "TREATMENT", 55, 69], ["the iWash application", "TREATMENT", 75, 96]]], ["We evaluated the systems on the test data mentioned in Section 5.3.", [["the test data", "TEST", 28, 41]]], ["A short description of the baselines are provided below:Compared Systems\u2022 WristWash: WristWash [14] is an handwashing quality assessment system that provides a Hidden MarkovCompared SystemsModel-based analysis for assessing the steps according to the WHO guidelines. \u2022 H2DTR-NN: This work [15] measures the duration and the quality of hand hygiene according to WHO guidelines using different techniques.", [["hand", "ANATOMY", 335, 339], ["hand", "ORGANISM_SUBDIVISION", 335, 339], ["an handwashing quality assessment", "TEST", 103, 136], ["different techniques", "TREATMENT", 382, 402]]], ["The best classification results were obtained using a neural network based solution and a k-nearest neighbor based solution.", [["neural network", "ANATOMY", 54, 68], ["a neural network based solution", "TREATMENT", 52, 83], ["a k-nearest neighbor based solution", "TREATMENT", 88, 123]]], ["H2DTR-NN represents the neural network based solution presented in the paper. \u2022 H2DTR-kNN: H2DTR-kNN represents the k-nearest neighbor based solution presented in above paper [15] .Compared SystemsAs per the implementation details described in these papers, both systems require a server where the model for assessing the handwashing quality is loaded and run.", [["neural network", "ANATOMY", 24, 38], ["H2DTR", "CHEMICAL", 0, 5], ["neural network", "MULTI-TISSUE_STRUCTURE", 24, 38], ["H2DTR", "PROTEIN", 0, 5], ["H2DTR-kNN: H2DTR-kNN", "DNA", 80, 100]]], ["In our implementation, the network bandwidth between the smartwatch and the server was 1 Gbps.Performance Metrics\u2022 Accuracy: To evaluate the performances of the systems in identifying the handwashing steps, we calculate accuracy, a commonly used performance metric.", [["smartwatch", "DNA", 57, 67], ["accuracy", "TEST", 220, 228]]], ["Accuracy of a handwashing step is defined as:Performance MetricsAccuracy of a step = Number of times the step was identified correctly Total number of times the step appeared in the handwashing data (3)Performance Metrics\u2022 Prediction latency: It measures the average time required by the system to provide the quality result of a handwashing event to the user. \u2022 Battery usage: It measures the amount of the battery consumed by the handwashing quality assessment system on the smartwatch.AccuracyWe conducted thorough experiments to evaluate how accurately iWash assesses the quality of handwashing performed by an user compared to the state-of-the-art systems.", [["the handwashing quality assessment", "TEST", 428, 462]]], ["Moreover, as previous systems [14] have evaluated the accuracy performance for both user-independent and user-dependent models, we also conducted experiments in both settings to show the performance superiority achieved by iWash.AccuracyUser-independent Model: For the user-independent model, the leave-one-participant-out (LOPO) validation was carried out where the data from 13 participants were used for training, and data from the remaining participant was used for testing.", [["participants", "SPECIES", 380, 392], ["participant", "SPECIES", 445, 456], ["testing", "TEST", 470, 477]]], ["The process was repeated for every participant and the average accuracy score for each of the handwashing steps was calculated.", [["participant", "SPECIES", 35, 46]]], ["User-dependent Model: For the user-dependent model, each of the compared system was trained and evaluated using the data from each participant individually.", [["participant", "SPECIES", 131, 142]]], ["The process was conducted for every participant and the average accuracy score was calculated for each of handwashing steps.", [["participant", "SPECIES", 36, 47], ["the average accuracy score", "TEST", 52, 78]]], ["Figure 9 presents the results for the handwashing steps detection accuracy of the systems for user-dependent model.", [["user-dependent model", "TREATMENT", 94, 114]]], ["On average, iWash provided around 15.6%, 4.2%, and 5.7% higher accuracy than WristWash, H2DTR-NN, and H2DTR-kNN, respectively.", [["iWash", "TEST", 12, 17], ["WristWash", "TEST", 77, 86], ["H2DTR", "TEST", 88, 93]]], ["The superior performance of iWash occurred for the same reason as described in the user-independent model.", [["iWash", "CHEMICAL", 28, 33], ["iWash", "PROTEIN", 28, 33], ["superior", "OBSERVATION_MODIFIER", 4, 12], ["iWash", "OBSERVATION", 28, 33]]], ["Also, each of the systems provided at least 4% accuracy improvement in the user-dependent model than its corresponding user-independent model.", [["improvement", "OBSERVATION_MODIFIER", 56, 67], ["dependent model", "OBSERVATION_MODIFIER", 80, 95]]], ["This happened because the user-dependent model that has been trained on only a single individual's handwashing data, can better capture his/her unique features of hand movement during handwashing.Prediction LatencyThe time required by the system to provide the handwashing quality result to user was measured for iWash and for the compared systems.", [["hand", "ANATOMY", 163, 167], ["hand", "ORGANISM_SUBDIVISION", 163, 167]]], ["Figure 10 shows the performances of iWash and the compared systems in terms of prediction latency. iWash provided around 46.2%, 50.1%, and 36.7% improvement in prediction latency compared to WristWash, H2DTR-NN, and H2DTR-kNN, respectively.", [["H2DTR-kNN", "SIMPLE_CHEMICAL", 216, 225], ["WristWash, H2DTR-NN, and H2DTR-kNN", "DNA", 191, 225], ["prediction latency", "TEST", 160, 178], ["WristWash", "TEST", 191, 200], ["H2DTR", "TEST", 202, 207]]], ["To show the effectiveness of iWash for use in daily life, we evaluated the daily battery usage of the iWash compared to the state-of-the-art systems, which is demonstrated in Figure 11 .", [["iWash", "CHEMICAL", 29, 34], ["iWash", "SIMPLE_CHEMICAL", 29, 34]]], ["Each of compared systems were installed at a time on the smartwatch for evaluation.", [["evaluation", "TEST", 72, 82]]], ["The intuition behind this is that, according to previous study, on average a person washes hands 10 times a day [35] .", [["person", "SPECIES", 77, 83], ["previous study", "TEST", 48, 62]]], ["The result shows that without having any of the systems installed, the battery level of the smartwatch fell to 26% by the end of the day, whereas using iWash, the battery level of the smartwatch fell to 22% by the end of the day.", [["the battery level", "TEST", 67, 84], ["the smartwatch", "TEST", 88, 102]]], ["Thus, it is evident that iWash does not consume any significant battery for the daily life use, while providing a handwashing assessment system to the user on the smartwatch with high accuracy and low prediction latency.", [["a handwashing assessment system", "TEST", 112, 143]]], ["On the other hand, using the other compared systems, the battery level dropped to a level of 8% to 10% making those systems less effective for daily basis usage.", [["the battery level", "TEST", 53, 70]]], ["Now-a-days, most of the people use multiple apps on smartwatch throughout a day [36] , this is where the additional battery level for iWash will be useful.", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30]]], ["The reason for the performance superiority of iWash is, unlike the other systems, iWash is optimized so that it effectively runs on the smartwatch with minimal battery usage.", [["iWash", "CHEMICAL", 46, 51], ["iWash", "SIMPLE_CHEMICAL", 46, 51]]], ["The number of FLOPs works as a delegate for prediction latency or consumed energy [37] .", [["FLOPs", "PROTEIN", 14, 19]]], ["The greater the number of FLOPs, the higher the prediction latency or consumed energy is.", [["greater", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 16, 22]]], ["As explained in Section 4.3, the hyper-parameter \u03b1 introduces a trade-off between accuracy and the number of FLOPs in the deep learning model of iWash.", [["iWash", "CANCER", 145, 150], ["hyper-parameter \u03b1", "PROTEIN", 33, 50], ["accuracy", "TEST", 82, 90], ["FLOPs", "TREATMENT", 109, 114], ["deep", "ANATOMY_MODIFIER", 122, 126]]], ["We observe that with the increase of the value of \u03b1, the accuracy increased, but the number of FLOPs also increased which in turn increased the prediction latency or battery usage of iWash.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 50, 51], ["FLOPs", "GENE_OR_GENE_PRODUCT", 95, 100], ["\u03b1", "PROTEIN", 50, 51], ["FLOPs", "PROTEIN", 95, 100], ["iWash", "PROTEIN", 183, 188], ["the accuracy", "TEST", 53, 65], ["the prediction latency", "PROBLEM", 140, 162], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["increased", "OBSERVATION_MODIFIER", 130, 139]]], ["This occurred because with the increase of \u03b1, the model was allowed to be more complex facilitating higher accuracy, albeit requiring higher computation.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 43, 44], ["\u03b1", "PROTEIN", 43, 44], ["higher computation", "TREATMENT", 134, 152]]], ["By controlling the value of \u03b1, we can fulfill the resource constraints of a low-resource device like a smartwatch.", [["\u03b1", "PROTEIN", 28, 29], ["a low-resource device", "TREATMENT", 74, 95]]], ["In our current implementation, we consider the value of \u03b1 as 0.5.", [["the value", "TEST", 43, 52]]], ["If a smartwatch has less resources or we need to make further room for other applications running on the device, we can consider the value of \u03b1 less than 0.5.", [["the device", "TREATMENT", 101, 111], ["the value", "TEST", 129, 138]]], ["From Figure 12 , we observe that, when the value of \u03b1 decreased from 0.5 to 0.3, number of FLOPs decreased by around 41%, but accuracy decreased by only 1.2%.", [["the value", "TEST", 39, 48], ["FLOPs", "TEST", 91, 96], ["accuracy", "TEST", 126, 134]]], ["Thus, by sacrificing accuracy a little, we can further decrease the battery usage of iWash.", [["iWash", "GENE_OR_GENE_PRODUCT", 85, 90]]], ["Similarly, for future smartwatches that are expected to have higher battery resources, we can consider a higher value of \u03b1 that allows achieving higher accuracy.", [["\u03b1", "PROTEIN", 121, 122]]], ["The baseline systems do not have such device adaptivity and, hence, we do not report them in this experiment.Overall ResultsOverall, the results show that iWash is a comprehensive system that overcomes several limitations of the state-of-the-art handwashing assessment systems in the context of the infectious diseases.", [["infectious diseases", "DISEASE", 299, 318], ["such device adaptivity", "TREATMENT", 33, 55], ["the infectious diseases", "PROBLEM", 295, 318], ["infectious", "OBSERVATION", 299, 309]]], ["Section 5.5.1 shows that iWash is able to detect the handwashing steps according to the WHO guidelines with a significantly higher accuracy than the other systems for different settings.", [["Section", "TEST", 0, 7]]], ["Section 5.5.4 shows that iWash can be tuned to adapt as per the resource availability of the devices unlike the state-of-the-art systems which offers no flexibility.Overall Results6 Related WorkCamera-based Handwashing Quality Assessment SystemsMany past works on handwashing quality assessment are based on a camera or vision based systems.", [["iWash", "SIMPLE_CHEMICAL", 25, 30], ["Section", "TEST", 0, 7], ["the devices", "TREATMENT", 89, 100], ["handwashing quality assessment", "TEST", 264, 294]]], ["These approaches usually require a video camera or a depth sensor camera to be placed above the sink [11] [12] [13] [38] .", [["a video camera", "TREATMENT", 33, 47], ["a depth sensor camera", "TREATMENT", 51, 72]]], ["The camera records the hand movements performed by the user during the hand hygiene activity.", [["hand", "ANATOMY", 23, 27], ["hand", "ANATOMY", 71, 75], ["hand", "ORGANISM_SUBDIVISION", 23, 27], ["hand", "ORGANISM_SUBDIVISION", 71, 75]]], ["The images or videos from the camera are sent to a cloud server, where the data is processed using vision-based approaches to assess the hand hygiene activities.", [["hand", "ANATOMY", 137, 141], ["hand", "ORGANISM_SUBDIVISION", 137, 141], ["The images", "TEST", 0, 10], ["the camera", "TEST", 26, 36]]], ["For example, Llorca et al [11] used such an approach using a RGB camera to access the hand hygiene activities of the healthcare workers.", [["hand", "ANATOMY", 86, 90], ["hand", "ORGANISM_SUBDIVISION", 86, 90], ["an approach", "TREATMENT", 41, 52], ["a RGB camera", "TREATMENT", 59, 71]]], ["Xia et al [12] used similar approaches to recognize hand hygiene poses using RGB-D Videos.", [["hand", "ANATOMY", 52, 56], ["hand", "ORGANISM_SUBDIVISION", 52, 56]]], ["However, there are several reasons such approaches are not suitable for daily life settings.", [["daily life settings", "TREATMENT", 72, 91]]], ["For example, a camera-based system will not work when the user is outside the home or when the user follows the hand rubbing approach which does not require a sink.", [["hand", "ANATOMY", 112, 116], ["hand", "ORGANISM_SUBDIVISION", 112, 116]]], ["Third, such approaches require substantial installation and maintenance costs [39] , as well as involves heavy computation for the analysis of images and videos.Wearable-based Handwashing Quality Assessment and Reminder SystemsSeveral wearables-based systems [14] [15] [16] [17] have been employed for the assessment of handwashing quality.", [["[14] [15] [16] [17]", "SIMPLE_CHEMICAL", 259, 278], ["substantial installation", "TREATMENT", 31, 55], ["the analysis of images", "TEST", 127, 149], ["Assessment", "TEST", 196, 206], ["the assessment", "TEST", 302, 316]]], ["This approach usually collects the wrist movements data during a handwashing event using the wrist-worn sensors and then uses different techniques for detecting the handwashing steps from the event according to the WHO guidelines.", [["wrist", "ANATOMY", 35, 40], ["wrist", "ORGANISM_SUBDIVISION", 35, 40], ["wrist", "ORGANISM_SUBDIVISION", 93, 98], ["the wrist-worn sensors", "TREATMENT", 89, 111], ["different techniques", "TREATMENT", 126, 146], ["wrist", "ANATOMY", 35, 40], ["wrist", "ANATOMY", 93, 98]]], ["WristWash [14] is a wrist-worn platform that provides offline analysis for assessing the steps according the WHO guidelines using Hidden Markov Model-based method.", [["offline analysis", "TEST", 54, 70], ["wrist", "ANATOMY", 20, 25]]], ["Galluzzi et al [15] used different machine learning based techniques for recognizing the handwashing duration and steps according to the WHO guidelines using the wrist-worn sensors.", [["wrist", "ORGANISM_SUBDIVISION", 162, 167], ["Galluzzi et al [", "TREATMENT", 0, 16], ["learning based techniques", "TREATMENT", 43, 68], ["wrist", "ANATOMY", 162, 167]]], ["However, there are several reasons why all these systems are not comprehensive enough in the context of infectious diseases.", [["infectious diseases", "DISEASE", 104, 123], ["infectious diseases", "PROBLEM", 104, 123], ["infectious", "OBSERVATION", 104, 114]]], ["First, most of these works are limited to offline analysis only and none of these provide any feedback to the user whether he/she washed hands properly.", [["hands", "ORGANISM_SUBDIVISION", 137, 142], ["offline analysis", "TEST", 42, 58]]], ["Second, none of these systems focused on optimizing the systems for running efficiently on smartwatches in addition to guaranteeing accuracy.", [["smartwatches", "TREATMENT", 91, 103]]], ["Compared to these systems, we achieve higher accuracy for quality assessment, as well as minimize the smartwatch processing time and battery usage to facilitate the immediate feedback.", [["quality assessment", "TEST", 58, 76], ["the smartwatch processing time", "TREATMENT", 98, 128]]], ["Moreover, in the context of infectious diseases, our system provide the feedback to the users in real-time if he/she did not wash hands properly, reminds the users when entering home and offers touch-free interaction with the user.Other ApproachesIn the past, adherence to the WHO guidelines was also measured from the direct observation by trained auditors [8] [9] [10] .", [["infectious diseases", "DISEASE", 28, 47], ["infectious diseases", "PROBLEM", 28, 47], ["infectious", "OBSERVATION", 28, 38]]], ["However, such approaches are not ubiquitous, and can not detect if the user performed the handwashing properly.Handwashing Applications since the COVID-19 OutbreakSince the COVID-19 outbreak, measures for spreading handwashing awareness and to improve handwashing practice have become widespread.", [["the COVID", "TREATMENT", 142, 151], ["the COVID", "TREATMENT", 169, 178], ["widespread", "OBSERVATION_MODIFIER", 285, 295]]], ["However, so far none of these companies have found an established solution to assess the quality of handwashing with respect to the standard guidelines or to provide any feedback to the user whether he/she washed hands properly.", [["hands", "ORGANISM_SUBDIVISION", 213, 218]]], ["Nevertheless, the current trend of the industry shows the promise of smartwatch based handwashing applications for the future.Discussion and Future Work\u2022 Potential use-cases of iWash: The performance superiority achieved by iWash will also be very significant in clinical environments, that is for healthcare workers where hand hygiene measures needs to be strictly followed.Discussion and Future WorkA study [45] shows that the daily average work shift duration of an healthcare worker is 12 hours.", [["hand", "ANATOMY", 323, 327], ["hand", "ORGANISM_SUBDIVISION", 323, 327], ["hand hygiene measures", "TREATMENT", 323, 344], ["Future WorkA study", "TEST", 390, 408]]], ["The battery usage evaluation of iWash shows that the smartwatch battery level with the iWash installed and used on a regular basis can last for the whole day.", [["The battery usage evaluation", "TEST", 0, 28], ["the smartwatch battery level", "PROBLEM", 49, 77]]], ["Therefore, iWash can be effectively worn by a healthcare worker, while it can provide them feedback about their handwashing quality with a high accuracy, which will help reduce the healthcare-associated infections.", [["infections", "DISEASE", 203, 213], ["iWash", "SIMPLE_CHEMICAL", 11, 16], ["associated infections", "PROBLEM", 192, 213], ["infections", "OBSERVATION", 203, 213]]], ["Moreover, previous studies [36] have shown that the average daily wear times of a smartwatch are typically 8-10 hours depending on the weekend/weekdays.", [["previous studies", "TEST", 10, 26]]], ["Since iWash does not consume any significant amount of battery life (Section 5.5.3) compared to not having a handwashing quality assessment system, it will be very effective for improving the hand hygiene practice in daily life. \u2022 Privacy: The whole system is deployed in smartwatch and requires no connection with any third-party entity (e.g., cloud provider).", [["hand", "ANATOMY", 192, 196], ["hand", "ORGANISM_SUBDIVISION", 192, 196], ["a handwashing quality assessment system", "TEST", 107, 146], ["no", "UNCERTAINTY", 296, 298]]], ["Thus, handwashing data do not leave the smartwatch and privacy of user data is ensured. \u2022 Evaluation of iWash for both hands: Since washing hands involves movement of both hands, using data from both wrists would provide better performance in assessing the quality of the handwashing events.", [["wrists", "ORGANISM_SUBDIVISION", 200, 206], ["Evaluation", "TEST", 90, 100], ["both hands", "ANATOMY", 167, 177], ["wrists", "ANATOMY", 200, 206]]], ["However, it is not practical to wear smartwatches on both hands, particularly in free living context.", [["hands", "ORGANISM_SUBDIVISION", 58, 63], ["hands", "ANATOMY", 58, 63]]], ["Our system requires the user to wear the smartwatch only on one wrist.", [["wrist", "ANATOMY", 64, 69], ["wrist", "ORGANISM_SUBDIVISION", 64, 69], ["the smartwatch", "TREATMENT", 37, 51], ["wrist", "ANATOMY", 64, 69]]], ["In this work, we evaluated our system on the data collected from the right hand.", [["right hand", "ANATOMY", 69, 79], ["hand", "ORGANISM_SUBDIVISION", 75, 79], ["the data", "TEST", 41, 49], ["right", "ANATOMY_MODIFIER", 69, 74], ["hand", "ANATOMY", 75, 79]]], ["Considering the fact that our method is agnostic to the placement of the watch, it would also work for the left hand.", [["left hand", "ANATOMY", 107, 116], ["hand", "ORGANISM_SUBDIVISION", 112, 116], ["left", "ANATOMY_MODIFIER", 107, 111], ["hand", "ANATOMY", 112, 116]]], ["In future, we will perform evaluations for the left hand too. \u2022 Larger user study in the context of infectious diseases: The focus of this work is to develop a comprehensive system for handwashing quality assessment on a smartwatch, that is more accurate, runs faster and consumes less battery compared to the state-of-the-art, as well as integrates context-aware reminder and touch-free interaction with the user.", [["left hand", "ANATOMY", 47, 56], ["infectious diseases", "DISEASE", 100, 119], ["hand", "ORGANISM_SUBDIVISION", 52, 56], ["evaluations", "TEST", 27, 38], ["Larger user study", "TEST", 64, 81], ["handwashing quality assessment", "TEST", 185, 215], ["left", "ANATOMY_MODIFIER", 47, 51], ["hand", "ANATOMY", 52, 56], ["infectious", "OBSERVATION", 100, 110]]], ["Applying the system on a larger group of people will be the next step to demonstrate its capability in reducing the spread of infectious diseases -which is beyond the scope of this paper. \u2022 Voice-based cognitive assistant: Modern consumer-grade smartwatches have a built-in speaker and microphone.", [["infectious diseases", "DISEASE", 126, 145], ["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["infectious diseases", "PROBLEM", 126, 145], ["spread", "OBSERVATION_MODIFIER", 116, 122], ["infectious", "OBSERVATION", 126, 136]]], ["Using these, previous work [31] used the idea of voice-interactive assistants for stroke patients that can interact with the user about any query regarding the medication and exercise.", [["stroke", "DISEASE", 82, 88], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["the medication", "TREATMENT", 156, 170]]], ["Similar to that, iWash can be extended to a voice-based cognitive assistant for any pandemic situation.", [["iWash", "SIMPLE_CHEMICAL", 17, 22], ["any pandemic situation", "PROBLEM", 80, 102]]], ["Besides offering handwashing reminders and voice interaction, in future iWash can integrate up-to-date public information about the pandemic downloaded to the smartwatch daily, such as, the current status of the pandemic, current restrictions, etc. Users can then, at any time, ask for information from smartwatch on these topics and receive a verbal response.ConclusionProper handwashing is widely acknowledged to be one of the most important activities for reducing the spread of infection.", [["infection", "DISEASE", 482, 491], ["infection", "PROBLEM", 482, 491], ["infection", "OBSERVATION", 482, 491]]], ["To the best of our knowledge, iWash is the most comprehensive system for smartwatch handwashing quality assessment, that achieves significantly higher accuracy compared to the state-of-the-art handwashing quality assessment systems.", [["smartwatch handwashing quality assessment", "TEST", 73, 114]]], ["It also provides routine and contextaware reminders, and offers touch-free interaction.", [["routine and contextaware reminders", "TREATMENT", 17, 51]]], ["We collected real-life dataset and extensive evaluations on the dataset demonstrate that iWash achieves around 12% higher accuracy, 37% lower processing time, and 10% lower battery usage than the state-of-the-art handwashing quality assessment systems.", [["extensive evaluations", "TEST", 35, 56]]]]}